

Mimicking Halimane-Synthases: Monitoring a Cascade of Cyclizations plus Rearrangements from Epoxypolyprenes.


José F. Quilez del Moral^{†,*}, Victoriano Domingo[†], Álvaro Pérez[†], Kevin A. Martínez Andrade[†], Lourdes Enríquez[‡], Martín Jaraiz[‡], José Luis López-Pérez^{‡,*}, and Alejandro F. Barrero^{†,*}

[†]Department of Organic Chemistry, Institute of Biotechnology, University of Granada, 18071 Granada, Spain.

[‡]Department of Electronics, University of Valladolid, 47011 Valladolid, Spain.

[‡]Department of Pharmaceutical Sciences, IBSAL-CIETUS, University of Salamanca, 37007 Salamanca, Spain. Department of Pharmacology, Faculty of Medicine, University of Panama, Republic of Panama.

TOC GRAPHIC



ABSTRACT: We have developed and rationalized a biomimetic transformation mimicking halimane-synthases based on a Lewis acid-catalyzed cascade of cyclizations plus rearrangements of epoxypolyprenes. Two rings, three stereogenic centers and a new double bond were generated in a single chemical operation. Based on this cascade transformation, we achieved a unified strategy toward the stereoselective total syntheses of halimene-type terpenoids and analogues as a proof-of-concept

1 study. This method has been applied to the rapid synthesis of diterpene isotuberculosinol, a virulence
2 factor of *Mycobacterium tuberculosis* as representative example.
3
4
5

7 INTRODUCTION

9 Biomimetic strategies allow the construction of complex natural products in a minimum of steps. The
10 benefits of these processes are recognized worldwide, with the “atom and step economy” approach of
11 green chemistry which are of special interest.¹⁻⁴ In the field of terpenoid biogenesis, the generation of
12 the hopanoid skeleton by squalene cyclases, where five new cycles and up to nine stereogenic centers
13 are created constitutes an excellent example of the spectacular and potentiality of this process.^{3,5}
14 Challenged by these fascinating transformations, researchers have been trying to replicate the action of
15 these enzymes for over a century.³ Although the use of either Brønsted or Lewis acids have been by far
16 the most common method to achieve biomimetic polycyclizations of isoprenoids in the lab,^{3,6-16} other
17 astonishing protocols including those involving enzymes¹⁷⁻²⁰ and radical cyclizations have also been
18 reported.²¹⁻²³ An outstanding milestone in this synthetic effort was the achievement of enantioselective
19 cyclization protocols of some polyenes.²⁴⁻²⁹
20
21
22
23
24
25
26
27
28
29
30
31
32
33


34 Often oxidosqualene- and other terpene cyclases, in addition to cyclization processes, give rise to a
35 series of hydride and methyl shifts before releasing the final natural product. Up to seven of these
36 rearrangements take place in the biosynthesis of triterpene cucurbitanes.³⁰ Obviously, the difficulty of
37 reproducing these processes using chemical reagents involving cyclizations and rearrangements
38 increases significantly. In this regard, van Tamelen and Sharpless reported in 1969 that the treatment of
39 squalene 2,3-oxide with stannic chloride led to a mixture of cyclized products, including a rearranged
40 bicyclic alcohol possessing the halimane core.³¹ Apart from van Tamelen’s seminal work, to the best of
41 our knowledge, no precedents exist on addressing rationalized synthesis of “rearranged terpenes” using
42 this approach. However, efficient rearrangements of carbocations generated on previously cyclized
43 structures can be found in the literature.³¹⁻³⁷ Some of these non-enzymatic rearrangements can be
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 considered as nice examples of the minimal-enzymatic-assistance hypothesis,^{4,38} thus encouraging the
2 biomimetic pursuit of these complex reactions.
3

4 The bicyclic backbone **B** present in diterpene halimene-type skeleton is a common molecular
5 fragment conserved in important biologically active natural products³⁹⁻⁴⁴ (Figure 1a). Biosynthetically, it
6 must be derived from (*E,E,E*)-geranylgeranyl diphosphate through “halimane synthases” catalysis. This
7 process starts with a class II diterpene cyclase (DTC) mediated protonation of the terminal
8 isopropylidene to give a bicyclic carbocation intermediate which later suffers several rearrangements of
9 hydride and methyl groups.⁴⁵ Other common DTCs (such as copalyl synthases for example) only
10 produce diterpenes as labdanes by deprotonation of the labda-13-en-8-yl⁺ intermediate **A**. Among the
11 many substances presenting the halimene framework, diterpenes such as isotuberculosinol (**1**) and 1-
12 tuberculosinyladenosine were reported to be the virulence factors⁴² isolated from *Mycobacterium*
13 *tuberculosis* the causative agent of the human disease tuberculosis, a worldwide health threat
14 responsible for approximate 1.7 million deaths annually.⁴⁶ Due to their interest and structural
15 complexity of these substances, multistep synthesis or semi-synthesis has been developed.⁴⁷⁻⁴⁸
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Here, we describe our efforts to know to what extent the action of “halimane synthases” can be
33 mimicked in the laboratory *in vitro*, that is, to generate the bicyclic halimene skeleton starting from a
34 simple acyclic epoxypolyprene in a one-step cascade process including two head-tail cyclizations and
35 two or three 1,2-Wagner-Meerwein rearrangements (Figure 1b).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

a Biosynthesis of halimanes



b Synthesis of halimanes




Figure 1. Accessing to the halimane skeleton. **a**, Biosynthesis of the halimanes: some representative halimane-type terpenoids. **b**, Bionspired synthesis of halimanes: Is it achievable a tandem cyclization-rearrangement process leading to halimenes?

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Taking advantage of the tremendous effort devoted by chemists for decades to comprehend carbocationic polycyclizations and before starting any experimental tests, we evaluated and analysed the possible requirements that each of the agents involved in the cyclization process. Selection of the oxirane group as an initiator is fundamental in this strategy because it must provide the selective and soft formation of the initial acyclic carbocation by oxirane opening. Concerning the structural

1 requirements the acyclic precursor, the presence of unsaturations in the terminal “R” moiety, as in the
2 case of C20 geranylgeraniol derivatives or longer polyprenes, or functions containing heteroatoms
3 located close to the C–8 carbocation **II** should be avoided since they could favour subsequent
4 cyclizations or E1 deprotonations respectively (Figure 1b).^{26,49} With regard to the reaction medium, the
5 use of non-basic and poor nucleophilic solvents and low temperatures should help to induce the
6 rearrangement process by avoiding the E1 processes. Finally, considering the requirements for the acid
7 that mediates the process, it should be a Lewis acid that, after coordination to the oxirane, should permit
8 its opening and subsequent cyclization, and most importantly, should prevent any fast ligand
9 dissociation in the generated intermediate zwitterionic species resulting from the oxirane opening (**II**,
10 Figure 1b). This zwitterion possesses a carbocation and a metalanion-alkoxide, which will bear the
11 negative charge during the whole process. Thus, when the cyclization is over, the cation at C–8 in the
12 absence of any base or nucleophile could evolve to the rearranged products if the process is
13 energetically favourable. Although different rearrangements could be conceivable, the series of 1,2-
14 migrations of hydride and methyl groups leading to the different expected halimene skeletons seems to
15 be, a priori, stereoelectronically favoured (Scheme 2). Additionally, in our opinion, the negative charge
16 located at the metal bound to the oxygen may exert an electrostatic attraction on the bicyclic cation at
17 C–8, thus-favouring those rearrangements that bring the charges closer. This reasoning regarding the
18 role that the Lewis acid should exert in this process parallels the interesting rationalization provided by
19 Shenvi to account for their results on the aluminium Lewis acids-mediated tail-to-head transformations
20 of a nerolidol-based vinyl epoxide, mimicking class I terpene cyclases.¹⁴ Thus, the authors claim that
21 key to the success of their approach was the “*sequestration of the counteranion using non-dissociating*
22 *ligands*”. Eventually, and after prolonged reaction times, the dissociation of a chloride ion from the
23 aluminate anion could be responsible for the ultimate deprotonation leading to the halimene skeleton.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS AND DISCUSSION

To verify the experimental viability of our hypothesis, we started this biomimetic approach by choosing the monoepoxide of farnesylbutane **2** as a simple model of a starting material. For the Lewis acid, we selected initially Me_2AlCl .⁵⁰ When **2** was made to react with 1.0 equiv of Me_2AlCl at $-78\text{ }^\circ\text{C}$ in DCM (0.1 M) for 40 min, an equimolecular mixture of epimers at C-8, **3a–3b** possessing the rearranged skeleton of halima-5-ene and *syn*- halima-5-ene was obtained in 51% yield (Table 1, entry 1), together with minor proportions of the non-rearranged monocyclic (**7b**) and bicyclic products (**8b**) (3% and 2%, respectively), as well as the acyclic aldehyde **6** (1.5%). The different mechanistic steps rationalizing the generation of the products obtained in this transformation are depicted in Scheme 1.

Scheme 1. Mechanistic Steps Leading to the Generation of 3–9.



Compound **3b** turned out to present a restricted conformational equilibrium at rt on ring B and as consequence the resolution of NMR spectra, especially in ^{13}C NMR, is low. A complete characterization of this isomer was only possible after conducting the NMR experiences at $90\text{ }^\circ\text{C}$ in deuterated DMSO. Molecular Mechanics conformational search first and quantum chemical calculations then performed on **3a** and **3b** revealed the existence of two pairs of main conformers of similar stability (≤ 1 kcal/mol) for

1 each epimer. The energetic barrier calculated for **3a** (7.2 Kcal/mol) supports a rapid rate of
2 interconversion in agreement with the experimental data in NMR, whereas the interconversion barrier
3 between the two conformers of **3b** (14.0 kcal/mol) may well account for a slow conformational
4 equilibrium between these two species (see Supplementary Information). This phenomenon was
5 reported in related natural products presenting the stereochemistry assigned to **3b**.^{19,40a}
6
7
8
9
10

11 In order to gain a comprehensive mechanistic and energetic understanding of the different steps of the
12 bicyclization-rearrangement cascade from **2** to **3a–3b**, quantum chemical calculations were carried out
13 using 14,15-epoxygeranylcitronelene (**I**) as a diterpene model and Me₂AlCl as a catalyst. Previous
14 inexpensive SCW calculations allowed us to find two main productive prochiral conformations (**Ia** and
15 **Ib**) of the acyclic precursor, namely, chair-boat and chair-chair conformations, both possessing similar
16 stabilities (difference 0.3 Kcal/mol, Figure 2). The results obtained from the computational study of the
17 entire process are represented in Figure 2 (see Supplementary Information for details).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2. Energy diagram for the formation of species I–X leading to halimenes 3a–b. Relative energies [kcal/mol, B3LYP/6-31+G(d,p) empirical dispersion=gd3b], in normal text for SMD solvation model by a single point energy calculation, and in brackets for calculations in vacuo. Selected distances in Å in TSs. For simplification of the figure, the moiety ClMe₂Al–O appears represented by L, and R stands for *n*-butyl.

Calculations showed differing results considering the generation of the labdan-8-yl cationic intermediate **III**. Thus, whereas the calculations performed in vacuum showed that the two cyclizations were stepwise, no minimum of energy was found for this first cyclization when the calculations were performed considering the presence of CH₂Cl₂ (concerted process). Although the concerted asynchronous processes were the result obtained when the solvent was included in the calculations,⁵¹⁻⁵² the feasibility of a stepwise scenario⁵³ should not be ruled out, mainly when this mechanism would well account for the generation of minor monocyclic products **4**, **5**, **7** and aldehyde **6**, found in the reaction of **2** with Me₂AlCl.

After the formation of bicyclic cations **IIIa** and **IIIb**, one 1,2 hydride C₉ → C₈ shift followed by a 1,2-methyl C₁₀ → C₉ migration were predicted to take place, overcoming small barriers leading to the haliman-10-yl carbocations **Va** and **Vb**. Rearranged intermediates **Va** and **Vb** undergo a ring A conformational change implying a variation of the space disposition of the dimethylchloroaluminate group from equatorial towards an axial arrangement. As consequence of this conformational change, the chlorine atom gradually approaches to C-10 carbocation, thus contributing to the stabilization of the intermediates **VII** due to the favourable electrostatic interactions between the negative charge of the chlorine atom partially detached from the alcoxyluminate and the carbocation at C-10. In fact, the initial distance of Al-Cl, (2.27Å) when the aluminate was equatorially disposed, is gradually lengthened to 2.53Å when it is axial in both intermediates **VIIa** and **VIIb**, while the distance C10-Cl, 1.99Å, is still far from the 1.85Å of a typical C_{sp3}-Cl bond. The fact that the chlorine atom is not completely detached from the aluminate anion is of paramount importance, since it not only permits the cascade of Warner-Meerwein rearrangements of the molecule to continue; but it also favours the interconversion of carbocations **VII** to **VIII** through C₅ → C₁₀ hydride shift from the alpha face of the halimane skeleton, a process thermodynamically favourable in 6 kcal/mol. Subsequently, the C3-C4 bond of **VIII** undergoes a gradual elongation until it breaks to give a 10-12 Kcal/mol more stable seco-3,4-halimane monocyclic aldehyde complex intermediates **IX**.

In this regard, a related A contraction of a halima-13*E*-en-15-PP-5-yl⁺ intermediate was proposed to occur in the biosynthesis of premutilin, proposal that was supported by quantum chemical calculations.⁵⁴ All that led us to hypothesize that the theoretically-proposed route to aldehydes **IX** may constitute a possible biosynthetic pathway to natural 3,4-*seco*-halimanes such as *secochiliotrin* methyl ester or *secochiliolide* aldehyde.⁶⁷



The unsaturated aldehydes **IX** suffer a concerted process with activation energy near to 10 kcal/mol where A ring is regenerated through a intramolecular Prins reaction with a simultaneous proton transfer from C-6 (H β -6) to O-3 to produce the final $\Delta^{5,6}$ halimanes **X**. It is worth noting that the particular space orientation of the oxygen atom resulted in the Prins process in TS_{IX-X}, which facilitated the final proton transfer.

These computational calculations are consistent with those recently reported on biosynthetic studies of halimenes not oxygenated at C3^{19,55} and, more significantly, they shed some light on the three most relevant figures of our cyclization-rearrangement experimental process. Thus, the solvent CH₂Cl₂ plays an important role provoking a significant decrease in the energetic barriers to cyclizations and rearrangements, probably as consequence of carbocation stabilization. Secondly, the formation of two stereoisomers at C8, **3a** and **3b**, is a consequence of the co-existence of a pre-chair-boat **Ia** acyclic precursor competing against the pre-chair-chair **Ib** precursor (both initial precursors and transition-states structures for the first cyclization step were predicted to be almost isoenergetic, see Supplementary Information). Furthermore, the role played by the oxygen and chlorine atoms in the non-detached


1 alkoxyaluminate anion, possibilitating the A ring opening and the ensuing concerted Prins reaction and
2 H6-deprotonation, supported the high selectivity observed toward haliman-5-enes among all the
3 possible olefinic regioisomers and also versus other kinds of rearranged products. Finally, the recovery
4 of the Lewis acid unaltered renders the process susceptible to catalysis by the Lewis acid.
5
6
7
8

9 Once we proved that the mechanism and the energetic barriers calculated for the cyclization and
10 rearrangement processes supported the experimental results obtained with model **2**, we focused our
11 efforts on optimizing the experimental conditions for this transformation. To this end, a screening of
12 different Lewis acids, concentrations, temperatures and solvents was achieved (Table 1).
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Screen of the Cyclization-Rearrangement Experimental Conditions of Epoxide 2

entry	equiv/LA	temp (°C), C (mM)	solvent	time (min)	3a, 3b yield (ratio)	4, 5, 6 yield (ratio)	7a, 7b yield (ratio)	8a, 8b, 8c yield (ratio)
1	1/Me ₂ AlCl	-78, 0.03	DCM	45	51% (1:1)	2% (0:0:1)	3% (1:0)	2% (1:0:0)
2	1/Et ₂ AlCl	-78, 0.03	DCM	45	54% (1:1.1)	3% (1:0:0.2)	ND	10% (0:0.6:1)
3	0.1/Bi(OTf) ₃	Reflux, 0.03	DCM	40	ND	4% (1:0:0)	4% (1:0)	23% (1:0:0)
4	1/Cu(OTf) ₂	-78, 0.03	DCM	30	ND	ND	19% (1:0.3)	17% (5.7:0.2:1)
5 ^a	1/InBr ₃	-78, 0.03	DCM	300	27% (1:0.8)	4% (1:0:0)	ND	13% (0:0.3:1)
6 ^b	1/InBr ₃	RT, 0.03	DCM	100	37% (1:0.4)	7% (1:0:0)	9% (1:0.2)	9% (0:0.8:1)
7	0.5/Et₂AlCl	-78, 0.03	DCM	100	53% (1:1)	ND	ND	ND
8	1.5/Et ₂ AlCl	-78, 0.03	DCM	50	59% (1:1)	ND	3% (1:0)	2% (1:0:0)
9	2/Et₂AlCl	-78, 0.03	DCM	45	71% (1:1.1)	6% (1:0:1)	ND	10% (0:0.6:1)
10	3/Et ₂ AlCl	-78, v	DCM	40	65% (1:1)	5% (1:0:0.4)	ND	4% (0:0.3:1)
11	5/Et ₂ AlCl	-78, 0.03	DCM	35	59% (1:1)	ND	ND	ND
12	2/Et ₂ AlCl	-100, 0.03	DCM	60	34% (1:1)	ND	ND	ND
13	2/Et ₂ AlCl	0, 0.03	DCM	30	50% ((1:1)	7% (1:0:0.2)	ND	13% (0:0:1)
14	2/Et ₂ AlCl	-78, 0.3	DCM	25	63% (1:1)	ND	3% (1:0)	ND
15	2/Et ₂ AlCl	-78, 0.003	DCM	50	58% (1:1)	2% (1:0:0)	ND	ND
16 ^c	2/Et ₂ AlCl	-78, 0.03	Hexane	60	27% (1:1)	ND	ND	ND
17	2/Et ₂ AlCl	10, 0.03	Bencene	45	54%(1:0.8)	5%(0.7:1:0)	ND	ND
18	2/Et ₂ AlCl	-78, 0.03	Toluene	45	68% (1:1)	2%(1:0:0)	ND	ND
19	2/Et ₂ AlCl	-78, 0.03	TBME	50	4% (1:1)	ND	57 (1:1.3)	21%(0:1.6:1)
20 ^d	2/Et ₂ AlCl	-78, 0.03	THF	210	ND	4 (1:0:1)	4 (1:1:1)	ND
21	2/Et ₂ AlCl	-30, 0.03	DCE	30	40% (1:1.2)	ND	ND	7 (0:1:0)
22	2/Et ₂ AlCl	-20, 0.03	CCl ₄	30	56% (1:0.8)	5%(1:0:0)	ND	3 (0:0:1)
23	2/Et ₂ AlCl	-60, 0.03	CHCl ₃	70	59% (1:1.1)	2(1:0:0)	ND	7 (0:0:1)
24 ^e	2/Et ₂ AlCl	-40, 0.03	CH ₃ CN	65	ND	ND	ND	22 (1:0:0)

^a Compound **9a** was obtained in 14% yield. Minor proportions of its epimer at C8 was detected by NMR from the mixture. ^b Compound **9a** was obtained in 15% yield. Its epimer at C8 was detected by NMR from the mixture. ^c 60% recovered starting material. ^d Compound **10** was obtained in 91% yield ^e Compound **11** was obtained in 43% yield.



To start, several Lewis acids were tested to trigger the cyclization-rearrangement process (Table 1, entries 1–6). Although the two alkyl aluminum Lewis acids used led to acceptable yields of **3a** and **3b**, comparatively slight yield improvements were found when Et₂AlCl was used (Table 1, entry 2). Copper(II) and bismuth(III) triflates failed to produce the desired halimane derivatives, and a complex mixture of non-rearranged monocyclic and bicyclic structures was observed (Table 1, entries 3–4). The results obtained with InBr₃ deserve a special mention, where together with the previously generated halim-5-ene derivatives **3a** and **3b**, the formation of haliman-1(10)-enes **9a** and **9b** was observed (Table 1, entries 5–6). The greater volume of the Lewis acid in this case, hampering its approach to C-10 and therefore the stabilization of the carbocation at this position, may be postulated to rationalize these results.


All in all, Et₂AlCl was selected as catalyst of choice. Variations in the quantity of Et₂AlCl used (Table 1, entries 7–11) caused an improvement in the efficiency of the process. Thus, up to a 71% yield of the desired halim-5-enes was obtained when 2 equivalents of Lewis acid were used (Table 1, entry 9). Changes in the temperature do not produce significant yield differences (Table 1, entries 9, 12–13), with the best results being obtained when the reaction was conducted at -78° C. Furthermore, the influence of molar concentration on production of **3a** and **3b** was also moderate as can be concluded from the results obtained in entries 9, 14 and 15 of the Table 1.

Finally, significant alterations of the reaction outcome were revealed when different solvents were tested. Thus, the use of hexane as a solvent slowed down the process significantly, and after 1h, most of the starting material remained mainly unaltered (Table 1, entry 16). Good yields were obtained in benzene and toluene (54% and 68%, respectively) (Table 1, entries 17–18), probably due to the stabilization of carbocation intermediates. The effect of ethereal solvents was counter-productive and mainly regular mono- and unrearranged bicyclization products **7** and **8** were obtained (Table 1, entries 19–20). Easy deprotonation of the corresponding bicyclic cations by solvents acting as Brønsted bases may account for the observed reactivity. The use of THF provoked the production of acyclic ketone **10** as major product as result of a 1,2-hydride shift of the initial acyclic carbocation. Other halogenated

solvents were also tested and, although acceptable yields of the target **3a** and **3b** were produced (Table 1, entries 21–23), the efficiency of the process was slightly worse when compared to that found when using DCM. To conclude, a polar aprotic solvent such as CH₃CN was also made to react with epoxide **2** (Table 1, entry 24) and the initial carbocation was neutralized by a molecule of acetonitrile leading to the hydroxyacetamide **11** as a major product after work-up.

Once the experimental conditions were optimized (Table 1, entry 9), we proceeded to study the scope of the process by altering the side chain of the epoxyolyprene (Table 2)

Table 2. Scope of the Biomimetic Cyclization–Rearrangement of Epoxyolyprenes.^a




^a Conditions: epoxyolyprene (0.01 M), Et₂AlCl (2–3 equiv), CH₂Cl₂, -78°C, 45 min. The epimeric mixtures were separated by semipreparative HPLC. ^b Minor proportions of the corresponding epimer at C8 was detected by NMR from the mixture.

First of all the reaction of the *tert*-butyldimethylsilyl derivative of 10,11-epoxyfarnesol **12** with Et₂AlCl in CH₂Cl₂ only resulted in a mixture of bicyclization compounds, where no concomitant

rearrangement were produced, in agreement with previous reported results.^{13,56} The presence of a silyloxy group at C13 in compound **13** considerably reduced the efficiency of the process towards the halimene type products **14b** (20%), whilst when a double bond is located at C-14, as happens in **15**, an acceptable yield was again obtained (55% of halima-5-enes **16a-b**). In both cases, a certain degree of diastereoselectivity was noticed, favouring the rearranged structured derived from the chair-boat conformation of the starting epoxide (methyl groups at C8 and C9: *anti*). In the reaction of epoxyproleanatetraene **17** with Et₂AlCl, a good 75 % of a 1:1.3 mixture of the corresponding tetracyclic derivatives (**18a-b**) was obtained, which evidenced a high energetic barrier for a third cyclization in this case.⁵⁷

When the monoepoxy derivative of methyl geranylgeraniate (**19**) was used as a starting material, the diastereomer **20b** resulting from the expected cyclization-rearrangement was obtained in a 29% yield. It should be noted that the monocyclic ketone **21** (5.5%) was also obtained.




Perhaps the most elegant demonstration of the utility of this cascade of cyclizations plus rearrangements strategy is displayed in the straightforward synthesis of the interesting halim-5-ene isotuberculosinol (**1**). We also anticipated that, while addressing the synthesis of tuberculosinol, the natural halimene viterofolin E,⁵⁹ isolated from *Vitex rotundifolia*, could be produced en route (Scheme 2). With these targets in mind, we treated the monoepoxy derivative of geranylinalool (**22**) with Et₂AlAl in DCM at -78 °C. Unsurprisingly, the presence of a free hydroxyl group prevented the cyclization-rearrangement process to take place efficiently, and only 12% of the corresponding halim-5-enes (**23**) were produced. However, if the monoepoxy derivative of geranylinalool acetate **24** was subjected to the same conditions, an acceptable 53% yield of diastereoisomers **25** (1: 2.5) was obtained,

together minor proportions of **26** and **27**. Of these two diastereomers, compound **25a** presents the same stereochemistry at C-8 and C-9 as that exhibited by isotuberculosinol (**1**) (Scheme 2), whereas the second diastereomer, **25b**, shares the stereochemistry at C-8 and C-9 with viterofolin E. Reduction of **25b** with LAH allowed to complete the synthesis of viterofolin E as a mixture of epimers at C-13 (**23b**) in only two steps and 34% yield from epoxide **24**.


Continuing with the synthesis of isotuberculosinol, the pair of epimers **25** was deoxygenated following the modified Barton-McCombie procedure, and then reduced with LAH. Isotuberculosinol **1** was thus obtained in 65% yield for the last three steps and in an overall 10% yield from monoepoxyderivative **24**. The spectroscopic data of synthetic isotuberculosinol matched completely with those reported for the natural substance.⁴⁷ Together with isotuberculosinol, its 8-epi-isomer **1b** was isolated in 25% yield. Although this substance has not been described as natural product so far, it was enzymatically produced.⁶⁰

Scheme 2. Synthesis of (±) isotuberculosinol.



Once we proved that rearranged diterpenes can be produced after a tandem process of cyclization and rearrangements, we turned back (our attention) to one of the conclusions inferred from the computational calculations, namely, (that) the process is susceptible to catalysis by the Lewis acid. Thus, we treated epoxide to substoichiometric quantities of different Lewis acids (Table 3). Although the use of 50% mmol of dimethylaluminium chloride also produced **3a** and **3b** with acceptable yield (table 3, entry 1), when the quantity of dimethylaluminium chloride was lowered up to 0.2 equiv, the process showed no completion after 5h of reaction time, and 31% of starting material remained unaltered (Table 3, entry 2). We decided then to test different gallium⁶⁶ and indium halides. Although the use of indium halides (Table 3, entries 3–4) led to low yields of the rearranged products **3a** and **3b**, the use of 0.2 equiv of different gallium halides led, gratifyingly, to acceptable yields of the desired halim-5-ene derivatives (Table 3, entries 5–7). We finally found that the quantity of GaCl₃ could be reduced to 0.01 equiv without decreasing the yield of the halim-5-enes produced (Table 3, entry 8).

Table 3. Generation of Halim-5-enes derivatives (3a–3b) from Epoxide 2 Using Catalytic Quantities of Lewis Acids^a




entry	equiv/LA	temp (°C), time (min)	3a, 3b yield (ratio)
1	0.5/Me ₂ AlCl	-78, 100	53% (1:1)
2 ^b	0.2/Me ₂ AlCl	-78, 180	32% (1:1.7)
3	0.2/InI ₃	rt, 15	28 % (1:0.8)
4	0.2/InCl ₃	rt, 55	12% (1:2)
5	0.2/GaCl ₃	rt, 5	56% (1:1)
6	0.2/GaI ₃	rt, 5	53% (1:1)
7	0.2/GaBr ₃	rt, 5	54% (1:1)
8	0.1/GaCl ₃	rt, 5	55% (1:1)
9	0.01/GaCl ₃	rt, 5	51% (1:1)

^a DCM was used as solvent, 0.03 C (mM). ^b 31% of starting material was recovered.

Finally, considering both the enormous biosynthetic importance of the cyclization of squalene-2,3-oxide and the fact that its cyclization with SnCl₄ supposed the only precedent so far reported of cyclization and rearrangement to produce halim-5-enes, we decided to study the behavior of squalene-2,3-oxide (**28**) in the presence of aluminium and gallium Lewis acids. The results obtained are summarized in Scheme 3.

Scheme 3. Cyclization of oxidoaqualene with Et₂AlCl and GaCl₃.




^a Minor proportions of the corresponding epimer at C8 was detected by NMR from the mixture.

Although no reported by van Tamelen, monocycles **29** and **30** were found previously in the cyclizations of **28**, either triggered by different acids or in processes involving cyclases.^{62,63} Aldehyde **31** was described for the first time. Halim-5-ene **32** presented the same ¹H NMR signals to that of the halimene described by van Tamelem, which allowed us to assign unambiguously the stereochemistry of

the product reported by these authors. It should be noted that van Tamelen and Sharpless suggested the opposite configuration at C9 for this compound in their seminal contribution. Finally, the rearranged malabaricanes thalianol (**33**) and 14-epithalianol (**34**) were also produced in these transformations.^{64,68} Although van Tamelen amazingly assigned in 1966 the same rearranged malabaricane to the tricyclic compound generated in the reaction of squalene-2,3-oxide with SnCl₄, our work suggest that the same mixture of thalianol and 14-epithalianol could have been generated in the SnCl₄-mediated cyclization. To conclude, the yields of **32-34** and their corresponding stereochemistries seem to indicate that, on the one hand, the bicyclic cation derived from the chair-chair conformation of squalene-2,3-oxide evolves via a third cyclization to produce the rearranged malabaricanes **33** and **34**, after a hydride and methyl shift, and a proton elimination (Scheme 4). On the other hand, the bicyclic intermediated derived from chair-boat conformation of the acyclic precursor would undergo the corresponding 1,2-shifts to generate the halim-5-ene derivative **32**.

Scheme 4. Formation of **32-34** from epoxide **28**.



CONCLUSIONS

1
2
3 Nature produces numerous examples of rearranged diterpenes and triterpenes. In this regard, we prove
4 that rearranged halima-5-enes can be produced in a single synthetic step by reacting monoepoxy-
5 geranylgeraniol derivatives with appropriate Lewis acids, via a cascade of two cyclizations and three
6 rearrangements. The fact that we were capable to generate “in vitro” the halima-5-ene skeleton
7 constitutes a nice illustration of the theory of “minimal enzymatic assistance”, which was postulated to
8 define the action of cyclases in the generation of related natural products. Quantum chemical
9 calculations revealed, on the one hand, that the energetic barriers calculated for the cyclization and
10 rearrangements processes were low enough to support our mechanistic proposal and, on the other hand,
11 that the process was susceptible to catalysis by the Lewis acid. This last inference was confirmed
12 experimentally, and acceptable yields of rearranged halim-5-ene derivatives could be produced after
13 employing 0.01 equiv of GaCl₃.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

EXPERIMENTAL SECTION

General Remarks.

30
31
32
33
34 All air- and water-sensitive reactions were performed in flasks flame-dried under a positive flow of
35 argon and conducted under an argon atmosphere. The solvents used were purified according to standard
36 literature techniques and stored under argon. Anhydrous dichloromethane was distilled from calcium
37 hydride (5 % w/v) under positive pressure of nitrogen. THF was freshly distilled immediately prior to
38 use from sodium/benzophenone and strictly deoxygenated for 30 min under Argon. Reagents were
39 purchased at the higher commercial quality and used without further purification, unless otherwise
40 stated. Silica gel SDS 60 (35-70 μm) was used for flash column chromatography. Reactions were
41 monitored by thin layer chromatography (TLC) carried out on 0.25 mm E. Merck silica gel plates (60F-
42 254) using UV light as the visualizing agent and solutions of phosphomolybdic acid in ethanol. HPLC
43 with UV detection was used. Semi-preparative HPLC separation were carried out on a column (5 μm
44 Silica, 10 X 250 mm) at a flow rate of 2.0 mL/min in an Agilent Series 1100 instrument. NMR spectra
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 were performed with a Varian Direct Drive 600 (^1H 600 MHz/ ^{13}C 150 MHz), Varian Direct Drive 500
2 (^1H 500 MHz/ ^{13}C 125 MHz), Varian Direct Drive 400 (^1H 400 MHz/ ^{13}C 100 MHz) and Varian Inova
3 Unity (^1H 300 MHz/ ^{13}C 75 MHz) spectrometers. High-resolution MS were determined on an Autospec-
4 Q VG-Analytical (FISONS) mass spectrometer. DEPT 135 and two-dimensional (COSY, HSQC,
5 HMBC, NOESY) NMR spectroscopy were used where appropriate to assist the assignment of signals in
6 the ^1H and ^{13}C NMR spectra.
7
8
9
10
11
12
13
14
15

16 Preparation of polyenic precursors 35–38.

17
18 *(6E,10E)-2,6,10-Trimethylhexadeca-2,6,10-triene (35)*. To a solution of farnesyl acetate (1000 mg,
19 3.78 mmol) in 20 mL of THF cooled at 0°C was added 3.8 mL of Li_2CuCl_4 (0.38 mmol). The resulting
20 solution was cooled at -30°C and then, 2.83 mL of butylmagnesium chloride were added dropwise
21 (5.67 mmol). After stirring for 4 h, the reaction mixture was diluted with *tert*butyl methyl ether (MTBE)
22 (120 mL) and then washed with saturated aqueous NH_4Cl and brine. The organic layer was then dried
23 with anhydrous Na_2SO_4 and concentrated under reduced pressure. Purification by flash chromatography
24 with hexane (H) provided 971 mg of compound **35** (97%). Colourless oil. ^1H NMR (400 MHz, CDCl_3):
25 δ 5.15–5.08 (m, 3H), 2.11–2.04 (m, 4H), 2.01–1.97 (m, 6H), 1.68 (s, 3H), 1.60 (s, 9H), 1.36–1.26 (m,
26 6H), 0.88 (t, $J = 7.0$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 134.8 (C), 134.7 (C), 131.2 (C),
27 124.8 (CH), 124.4 (CH), 124.3 (CH), 39.7 (CH_2), 39.7 (CH_2), 31.5 (CH_2), 29.6 (CH_2), 27.9 (CH_2), 26.8
28 (CH_2), 26.6 (CH_2), 25.7 (CH_3), 22.6 (CH_2), 17.7 (CH_3), 16.0 (CH_3), 15.9 (CH_3), 14.1 (CH_3); HRMS
29 (ESI–QTOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{35}$ 263.2739, found 263.2732.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 *Tert-butyl dimethyl(((5E,9E)-6,10,14-trimethylpentadeca-5,9,13-trien-2-yl)oxy)silane (36)*. To a
47 solution of farnesyl ketone (1147 mg, 4.38 mmol) in 24 mL of THF cooled at 0°C was added 141 mg of
48 LAH (3.72 mmol). The resulting solution was stirred for 20 min, and then, diluted with MTBE. To this
49 solution, 0.1 mL of H_2O , 0.1 mL of 5N NaOH and 0.3 mL of H_2O were added successively. The
50 resulting mixture was filtrated through a pad Na_2SO_4 and silica gel and concentrated under reduced
51 pressure. To a stirred solution of this reaction crude oil in 70 mL of DMF were added imidazole (627
52
53
54
55
56
57
58
59
60

1 mg, 9.2 mmol) and TBSCl (1384 mg, 9.2 mmol). After consumption of the starting product (12 h), the
2 mixture was diluted with MTBE and water and extracted with MTBE. The combined organic layer was
3 washed with 2N HCl and brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure.
4
5 Purification by flash chromatography (H:MTBE, 3:1) afforded 1460 mg of compound **36** (88%).
6
7 Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.17–5.08 (m, 3H), 3.80 (sext, *J* = 6.1 Hz, 1H), 2.12–
8 1.92 (m, 10H), 1.69 (s, 3H), 1.61 (s, 9H), 1.53–1.67 (m, 2H), 1.14 (d, *J* = 6.1 Hz, 3H), 0.90 (s, 9H), 0.06
9 (s, 6H); ¹³C {¹H} NMR (125 MHz, CDCl₃): δ 135.0 (C), 134.9 (C), 131.2 (C), 124.4 (CH), 124.3 (CH),
10 124.2 (CH), 68.4 (CH), 39.9 (CH₂), 39.7 (CH₂), 39.7 (CH₂), 26.8 (CH₂), 26.6 (CH₂), 25.9 (3 x CH₃),
11 25.7 (CH₃), 24.3 (CH₂), 23.8 (CH₃), 18.2 (C), 17.7 (CH₃), 16.0 (CH₃), 16.0 (CH₃), -4.4 (CH₃), -4.7
12 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₂₄H₄₇OSi 379.3396, found 379.3391.
13
14
15
16
17
18
19
20
21
22

23 *(6E,10E)-3,7,11,15-Tetramethylhexadeca-1,6,10,14-tetraene (37)*. A mixture of Cp₂TiCl₂ (4124 mg,
24 16.56 mmol) and Mn dust (3163 mg, 57.61 mmol) in deoxygenated THF 100 mL) was stirred at rt until
25 the red solution turned green, under an argon atmosphere. Then, a solution of geranylgeraniol (2092 mg,
26 7.2 mmol) in strictly deoxygenated THF (5.0 mL) was added to the solution of Cp₂TiCl₂. The reaction
27 mixture was refluxed for 20 h. Then, the solution was diluted with MTBE, filtrated and the solid washed
28 with ethyl acetate. The organic layer was washed with HCl 2N, then with brine, dried over anhydrous
29 Na₂SO₄ and concentrated *in vacuo*. The resulting crude was flash chromatographed (H) to give 1007 mg
30 (51%) of compound **37**. Colourless oil. ¹H NMR (400 MHz, CDCl₃): δ 5.71 (ddd, *J* = 17.2, 10.3, 7.5 Hz,
31 1H), 5.16–5.08 (m, 3H), 4.96 (ddd, *J* = 17.2, 2.0, 1.2 Hz, 1H), 4.92 (ddd, *J* = 10.3, 2.0, 0.9 Hz, 1H),
32 2.17–1.96 (m, 11H), 1.68 (s, 3H), 1.60 (s, 9H), 1.38–1.27 (m, 2H), 0.97 (d, *J* = 6.7 Hz, 3H); ¹³C {¹H}
33 NMR (75 MHz, CDCl₃): δ 145.0 (CH), 135.1 (C), 131.5 (C), 124.8 (CH), 124.7 (CH), 124.5 (CH),
34 118.5 (C), 112.7 (CH₂), 46.0 (CH), 40.0 (CH₂), 37.6 (CH₃), 37.0 (CH₂), 27.0 (CH₂), 26.9 (CH₂), 26.0
35 (CH₃), 25.9 (CH₂), 20.4 (CH₃), 17.9 (CH₃), 16.3 (CH₃), 16.3 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺
36 Calcd for C₂₀H₃₅ 275.2739, found 275.2727.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 *Methyl (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenoate (38)*. To a stirred solution
56 of geranylgeraniol (1000 mg, 3.45 mmol) in 40 mL in CH₂Cl₂ under Argon was added Dess-Martin
57
58
59
60

1 reagent (2925 mg, 6.9 mmol). After 2 h at rt the reaction was quenched with a saturated solution of
2 $\text{Na}_2\text{S}_2\text{O}_3\text{-NaHCO}_3$ that was added slowly to the mixture, the combined organic layer was washed with
3
4 brine and dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. Filtration on silica gel
5
6 (H: MTBE, 1:2) afforded the allylic aldehyde, which was dissolved in 30 mL of *tert*-butyl alcohol and
7
8 15 mL of 2-methyl-2-butene. A solution of sodium chlorite (1910 mg, 21.22 mmol) and sodium
9
10 dihydrogenphosphate (2200 mg, 15.92 mmol) in 15 mL of water was added dropwise over a 25 min
11
12 period. The pale yellow reaction mixture was stirred at room temperature for 2 h. Volatile components
13
14 were then removed under vacuum. The residue was dissolved in 150 mL of water and extracted with
15
16 two 100 mL portions of MTBE. The combined organic layers were washed with brine, dried and
17
18 concentrated. To a stirred solution of this reaction crude oil in 8.5 mL of benzene and 2.1 mL of MeOH,
19
20 1.6 mL (3.2 mmol) of a 2M solution of TMSCH_2N_2 in hexanes was added dropwise. After consumption
21
22 of the starting product (30 min), the mixture was concentrated under reduced pressure. Purification by
23
24 flash chromatography (H/MTBE, 10:1) afforded 556 mg of compound **38** (51%). The spectroscopic data
25
26 of compound **38** coincide with those reported in the literature.⁵⁸
27
28
29
30
31
32
33
34

35 **General procedure for the synthesis of epoxy-derivatives 2, 13, 15 and 19**

36
37 Powdered NBS (1.1 mmol) was added to a solution of the corresponding polyene (**35–38**) (1.0 mmol)
38
39 in a mixture of THF:H₂O (12 mL, 5:1) at 0 °C. The mixture was stirred for 30 min, diluted with MTBE,
40
41 washed with water, dried with anhydrous Na_2SO_4 and the solvent concentrated under reduced pressure.
42
43 The residue was dissolved in 8 mL of MeOH containing 1.2 mmol of K_2CO_3 (20 mL) and stirred for 10
44
45 min. The methanolic solution was then diluted with MTBE, washed with water, brine, dried with
46
47 anhydrous Na_2SO_4 and the solvent removed, giving a residue which was flash chromatographed to give
48
49 the corresponding epoxides.
50
51

52
53 *(3-((3E,7E)-3,7-Dimethyltrideca-3,7-dien-1-yl)-2,2-dimethyloxirane (2)*. Following the general
54
55 procedure, successive reaction of polyene **28** with NBS and $\text{K}_2\text{CO}_3/\text{MeOH}$ provided compound **2**
56
57 (45%). This compound was separated by flash chromatography (H:MTBE, 95:5). Colourless oil. ¹H
58
59

1 NMR (300 MHz, CDCl₃): δ 5.17–5.11 (m, 2H), 2.70 (t, *J* = 6.2 Hz, 1H), 2.19–2.06 (m, 4H), 2.04–1.94
 2 (m, 4H), 1.70–1.63 (m, 2H), 1.62 (s, 3H), 1.59 (s, 3H), 1.33–1.27 (m, 6H), 1.30 (s, 3H), 1.26 (s, 3H),
 3 0.88 (t, *J* = 6.5 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 134.5 (C), 133.9 (C), 124.9 (CH), 124.9
 4 (CH), 64.2 (CH), 58.3 (C), 39.6 (CH₂), 36.3 (CH₂), 31.5 (CH₂), 29.5 (CH₂), 27.9 (CH₂), 27.5 (CH₂),
 5 26.6 (CH₂), 24.9 (CH₃), 22.6 (CH₂), 18.7 (CH₃), 16.0 (CH₃), 15.9 (CH₃), 14.1 (CH₃); HRMS (ESI-
 6 QTOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688, found 279.2681.

7
 8
 9
 10
 11
 12
 13
 14 *Tert-butyl(((5E,9E)-12-(3,3-dimethyloxiran-2-yl)-6,10-dimethyldodeca-5,9-dien-2-yl)oxy)dimethyl*
 15 *silane (13)*. Following the general procedure, successive reaction of polyene **29** with NBS and
 16 K₂CO₃/MeOH provided compound **13** (45%). This compound was separated by flash chromatography
 17 (H:MTBE, 95:5). Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.17 (bt, *J* = 6.8 Hz, 1H), 5.13 (bt, *J* =
 18 6.9 Hz, 1H), 3.80 (sext, *J* = 6.0 Hz, 1H), 2.71 (t, *J* = 6.3 Hz, 1H), 2.19–1.92 (m, 8H), 1.71–1.57 (m, 2H),
 19 1.63 (s, 3H), 1.61 (s, 3H), 1.53–1.39 (m, 2H), 1.31 (s, 3H), 1.27 (s, 3H), 1.14 (d, *J* = 6.1 Hz, 3H), 0.90
 20 (s, 9H), 0.6 (s, 6H); ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 134.9 (C), 134.0 (C), 124.9 (CH), 124.4 (CH),
 21 68.4 (CH), 64.2 (CH), 58.3 (C), 39.8 (CH₂), 39.6 (CH₂), 36.3 (CH₂), 27.5 (CH₂), 26.6 (CH₂), 25.9 (3 x
 22 CH₃), 24.9 (CH₃), 24.3 (CH₂), 23.8 (CH₃), 18.8 (CH₃), 18.2 (C), 16.0 (CH₃), 16.0 (CH₃), -4.4 (CH₃), -
 23 4.7 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₂₄H₄₇O₂Si 395.3345, Found 395.3355.

24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37 *2,2-Dimethyl-3-((3E,7E)-3,7,11-trimethyltrideca-3,7,12-trien-1-yl)oxirane (15)*. Following the general
 38 procedure, successive reaction of polyene **30** with NBS and K₂CO₃/MeOH provided compound **15**
 39 (58%). This compound was separated by flash chromatography (H:MTBE, 95:5). Colourless oil. ¹H
 40 NMR (300 MHz, CDCl₃): δ 5.74–5.63 (m, 1H), 5.17–5.08 (m, 2H), 4.97–4.89 (m, 2H), 2.69 (t, *J* = 6.2
 41 Hz, 1H), 2.15–2.04 (m, 6H), 2.00–1.92 (m, 5H), 1.66–1.63 (m, 2H), 1.61 (s, 3H), 1.58 (s, 1H), 1.35–
 42 1.30 (m, 2H), 1.29 (s, 3H), 1.25 (s, 3H), 0.98 (d, *J* = 6.7 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃): δ
 43 145.0, 135.0, 134.2, 125.1, 124.9, 112.7, 64.4, 58.5, 39.9, 37.6, 37.0, 36.6, 27.7, 26.8, 25.9, 25.1, 20.4,
 44 19.0, 16.3, 16.2; HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₂₀H₃₅O 291.2688, Found 291.2677.

45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55 *Methyl (2E,6E,10E)-13-(3,3-dimethyloxiran-2-yl)-3,7,11-trimethyltrideca-2,6,10-trienoate (19)*.
 56 Following the general procedure, successive reaction of polyene **31** with NBS and K₂CO₃/MeOH
 57
 58
 59
 60

provided compound **19** (34%). This compound was separated by flash chromatography (H:MTBE, 10:1). Colourless oil. ^1H NMR (500 MHz, CDCl_3): δ 5.68 (bs, 1H) 5.15 (bt, $J = 6.9$ Hz, 1H), 5.10 (m, 1H), 3.69 (s, 3H), 2.71 (t, $J = 6.2$ Hz, 1H), 2.19–1.97 (m, 10H), 2.17 (d, $J = 1.3$ Hz, 3H), 1.67–1.59 (m, 2H), 1.62 (s, 3H), 1.61 (s, 3H), 1.30 (s, 3H), 1.27 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 167.2 (C), 160.1 (C), 136.1 (C), 134.1 (C), 124.7 (CH), 122.9 (CH), 115.2 (CH), 64.2 (CH), 58.3 (C), 50.8 (CH₃), 40.9 (CH₂), 39.6 (CH₂), 36.3 (CH₂), 27.5 (CH₂), 26.6 (CH₂), 25.9 (CH₂), 24.9 (CH₃), 18.8 (CH₃), 18.7 (CH₃), 16.0 (CH₃), 16.0 (CH₃); HRMS (ESI–QTOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{35}\text{O}_3$ 335.2586, Found 335.2593.

Epoxides **12**, **17**, **22**, **24** and **28** were obtained following methods previously reported in the literature.^{13, 57, 61, 65}

General procedure for the cyclization plus rearrangement of epoxy polyprenes **2**, **12**, **13**, **15**, **17**, **19**, **24** and **26**.

A solution of starting material (0.5 mmol) in dry DCM (50 mL) was cooled at -78 °C, To a separate flask was added dry DCM (15 mL) followed by 1 mL of a 1M solution Et_2AlCl in DCM (1 mmol). This solution of Et_2AlCl was slowly added to a cooled solution of starting material (approximately for 1h). The reaction crude oil was further stirred until disappearance of the starting material. Then, 1.5 mL of Et_3N and 0.7 mL of a 4:1 mixture of MeOH/ H_2O were added. The reaction mixture was taken out of the cooling bath and a saturated solution of NH_4Cl (60 mL) was then added. After separation of the organic layer, the aqueous layer was extracted with DCM (2 x 50 mL). The combined organic layer was washed with brine (3 x 50 mL), dried over Na_2SO_4 , concentrated under reduced pressure and then purified by column chromatography.

Cyclization of epoxy polyprene **2**

Using DCM as solvent

Following the general procedure, reaction of epoxide **2** with Et₂AlCl at -78 °C for 1 h provided after flash chromatography (H:MTBE, 6:1) compounds **3a** and **3b** (71%, 1:1 ratio), compound **4** (3%), compound **6** (3%) and compounds **8b** and **8c** (10%, 0.6:1 ratio). Ratios were determined by integration of the ¹H NMR spectrum of the mixture.

(2*S*,4*aS*,5*R*,6*S*)-1,1,5,6-Tetramethyl-5-pentyl-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**3a**). A fraction enriched in **3a** was subjected to HPLC (normal phase, H:TBME 19:1, Rt = 50.1 min) to give pure **3a**. Colourless oil. ¹H NMR (600 MHz, CDCl₃): δ 5.53 (dt, *J* = 5.1, 2.2 Hz, 1H), 3.47 (t, *J* = 2.8 Hz, 1H), 2.27 – 2.22 (m, 1H), 1.92 – 1.85 (m, 2H), 1.79 (dddd, *J* = 17.7, 10.6, 3.5, 2.3 Hz, 1H), 1.70 (dq, *J* = 14.0, 3.5 Hz, 1H), 1.57–1.45 (m, 3H), 1.36 – 1.17 (m, 8H), 1.14 (s, 3H), 1.06 (s, 3H), 0.90 (t, *J* = 7.3 Hz, 3H), 0.81 (d, *J* = 6.8 Hz, 3H), 0.66 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃): δ 142.4 (C), 120.8 (CH), 76.4 (CH), 41.3 (C), 38.8 (CH), 37.0 (C), 36.8 (CH₂), 33.5 (CH), 32.8 (CH₂), 31.8 (CH₂), 28.3 (CH₃), 28.3 (CH₂), 25.5 (CH₃), 22.7 (CH₂), 22.2 (CH₂), 20.0 (CH₂), 16.3 (CH₃), 15.1 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688, Found 279.2682.

(2*S*,4*aS*,5*R*,6*R*)-1,1,5,6-Tetramethyl-5-pentyl-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**3b**). A fraction enriched in **3b** was subjected to HPLC (normal phase, H:MTBE 19:1, Rt = 50.1 min) to give pure **3b**. Colourless oil. ¹H NMR (600 MHz, DMSO-*d*₆, 85 °C): δ 5.27 (bt, *J* = 3.9 Hz, 1H, H₆), 3.32 (t, *J* = 3.1 Hz, 1H, H₃), 2.06 (bd, *J* = 17.4 Hz, 1H, H_{7a}), 1.98 (bd, *J* = 12.2 Hz, 1H, H₁₀), 1.92 (tdd, *J* = 13.2, 4.9, 2.6 Hz, 1H, H_{2a}), 1.68 – 1.55 (m, 3H, H_{7b}, H₈, H_{2b}), 1.52 – 1.40 (m, 2H, H₁), 1.31 – 1.13 (m, 8H, H₁₁, H₁₂, H₁₃, H₁₄), 1.01 (s, 3H, H₁₉), 0.98 (s, 3H, H₁₈), 0.85 (t, *J* = 7.1 Hz, 3H, H₁₅), 0.78 (s, 3H, H₂₀), 0.75 (d, *J* = 6.7 Hz, 3H, H₁₇); ¹³C{¹H} NMR (150 MHz, DMSO-*d*₆, 85 °C): δ 148.6 (C₆), 121.7 (C₅), 80.2 (C₃), 45.8 (C₄), 45.1 (C₁₀), 41.0 (C₉), 39.7 (C₁₁), 37.8 (C₈), 37.7 (CH₂), 36.0 (C₇), 34.8 (C₂), 32.3 (C₁₈), 30.2 (C₁₉), 27.6 (CH₂), 27.2 (CH₂), 27.0 (C₂₀), 26.7 (C₁), 19.7 (C₁₇), 19.0 (C₁₅); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688; Found 279.2679.

(1R,4S)-1,3,3-Trimethyl-2-((E)-3-methylnon-3-en-1-yl)-7-oxabicyclo[2.2.1]heptane (4). Colourless oil. ^1H NMR (600 MHz, CDCl_3): δ 5.17 (tm, $J = 6.9$ Hz, 1H), 3.70 (d, $J = 5.4$ Hz, 1H), 2.00 – 1.86 (m, 5H), 1.69 – 1.63(m, 1H), 1.57 (s, 3H), 1.50 – 1.22 (m, 10H), 1.31 (s, 3H), 1.17 (dd, $J = 8.7, 5.8$ Hz, 1H), 1.03 (s, 3H), 1.00 (s, 3H), 0.88 (t, $J = 7.1$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 135.0 (C), 133.8 (C), 125.0 (CH), 88.7 (C), 86.0 (CH), 55.1 (CH), 45.2 (C), 39.8 (CH_2), 39.0 (CH_2), 31.5 (CH_2), 29.5 (CH_2), 27.8 (CH_2), 26.1 (CH_2), 26.1 (CH_3), 25.7 (CH_2), 23.9 (CH_3), 22.6 (CH_2), 18.9 (CH_3), 15.9 (CH_3), 14.1 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{35}\text{O}$ 279.2688, Found 279.2710.

(R,E)-4,8-Dimethyl-5-(propan-2-ylidene)tetradec-8-enal (6). Aldehyde **6** was purified and characterized as its primary alcohol derivative **6a**. To a solution of a fraction enriched in **6** (18 mg) in 5 mL of $\text{MeOH}:\text{H}_2\text{O}$ (4:1 ratio) was added 3 mg of NaBH_4 and the mixture was stirred for 1 h 30 min at 0°C . The reaction was concentrated under reduced pressure and the residue dissolved in MTBE and washed with water, quenched with acetone, and concentrated under reduced pressure. The organic layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The resulting crude was purified by HPLC (H:MTBE, 6:1) to afford 12 mg of primary alcohol **6a**. Colourless oil. ^1H NMR (500 MHz, CDCl_3): δ 5.15 (t, $J = 7.1$ Hz, 1H), 3.62 (t, $J = 6.7$ Hz, 2H), 2.71 (h, $J = 7.1$ Hz, 1H), 2.06 – 1.93 (m, 4H), 1.68 (s, 3H), 1.65 (s, 3H) 1.63 (s, 3H), 1.55 – 1.25 (m, 10 H), 0.98 (d, $J = 6.9$ Hz, 3H), 0.90 (t, $J = 7.0$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3): δ 135.7 (C), 135.6 (C), 125.2 (C), 124.3 (CH), 63.4 (CH_2), 40.4 (CH_2), 35.6 (CH), 31.6 (CH_2), 31.6 (CH_2), 31.2 (CH_2), 29.6 (CH_2), 27.9 (CH_2), 27.0 (CH_2), 22.6 (CH_2), 21.0 (CH_3), 20.1 (CH_3), 19.7 (CH_3), 16.0 (CH_3), 14.1 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OH}]^+$ Calcd for $\text{C}_{19}\text{H}_{35}$ 263.2739, Found 263.2745.

(2S,4aR,5S,8aR)-1,1,4a-Trimethyl-6-methylene-5-pentyldecahydronaphthalen-2-ol (8b). A fraction enriched in **8b** was subjected to HPLC (normal phase, H:MTBE 9:1, $R_t = 22.7$ min) to give pure **8b**. Colourless oil. ^1H NMR (500 MHz, CDCl_3): δ 4.83 (d, $J = 1.7$ Hz, 1H), 4.53 (d, $J = 1.7$ Hz, 1H), 3.27 (dd, $J = 11.8, 4.4$ Hz, 1H), 2.43 – 2.38 (m, 1H), 1.99 (td, $J = 13.1, 5.0$ Hz, 1H), 1.81 (dt, $J = 13.1, 3.6$ Hz, 1H), 1.77 – 1.06 (m, 15H), 1.01 (s, 3H), 0.92 (s, 1H), 0.88 (t, $J = 7.1$ Hz, 3H), 0.78 (s, 3H), 0.68 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CDCl_3): δ 148.4 (C), 106.5 (CH_2), 78.9 (CH), 56.6 (CH), 54.6 (CH),

39.3 (C), 39.1 (C), 38.2 (CH₂), 37.1 (CH₂), 32.5 (CH₂), 28.4 (CH₂), 28.3 (CH₃), 28.0 (CH₂), 24.0 (CH₂),
23.7 (CH₂), 22.7 (CH₂), 15.4 (CH₃), 14.4 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) m/z: [M – OH]⁺
Calcd for C₁₉H₃₃ 261.2582, Found 261.2597.

(2*S*,4*aR*,5*S*,8*aR*)-1,1,4*a*,6-Tetramethyl-5-pentyl-1,2,3,4,4*a*,5,8,8*a*-octahydronaphthalen-2-ol (**8c**). A fraction enriched in **8c** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 21.5 min) to give pure **8c**. Colourless oil. ¹H NMR (600 MHz, CDCl₃): δ 5.39 (bs, 1H), 3.26 (dd, *J* = 11.2, 4.5 Hz, 1H), 2.00 – 1.94 (m, 2H), 1.91 (dt, *J* = 13.3, 3.6 Hz, 2H), 1.69 (s, 3H), 1.67 – 1.57 (m, 3H), 1.52 (s, 2H), 1.42 – 1.10 (m, 8H), 0.98 (s, 3H), 0.90 (t, *J* = 7.1 Hz, 3H), 0.87 (s, 3H), 0.76 (s, 3H); ¹³C {¹H} NMR (126 MHz, CDCl₃): δ 135.6 (C), 121.7 (CH), 79.2 (CH), 54.9 (CH), 49.6 (CH), 38.7 (C), 37.3 (CH₂), 36.5 (C), 32.5 (CH₂), 31.9 (CH₂), 27.9 (CH₃), 27.4 (CH₂), 27.2 (CH₂), 23.5 (CH₂), 22.6 (CH₂), 21.9 (CH₃), 15.1 (CH₃), 14.1 (CH₃), 13.5 (CH₃); HRMS (ESI-QTOF) m/z: [M – OH]⁺ Calcd for C₁₉H₃₃ 261.2582, Found 261.2608.

Using MTBE as solvent

Following the general procedure, reaction of epoxide **2** with Et₂AlCl, using MTBE as a solvent for 1 h provided after flash chromatography (H:MTBE, 9:1) compounds **3a** and **3b** (4%, 1:1 ratio), compounds **7a** and **7b** (57%, 1:1.3 ratio) and compounds **8b** and **8c** (21%, 1.6:1 ratio). Ratios were determined by integration of the ¹H NMR spectrum of the mixture.

(1*S*,5*R*)-4,6,6-Trimethyl-5-((*E*)-3-methylnon-3-en-1-yl)cyclohex-3-en-1-ol (**7a**). A fraction enriched in **7a** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 20.8 min) to give pure **7a**. Colourless oil. ¹H NMR (600 MHz, CDCl₃): δ 5.23 (bs, 1H), 5.13 (t, *J* = 6.8 Hz, 1H), 3.45 (dd, *J* = 8.1, 5.5 Hz, 1H), 2.26 – 2.19 (m, 1H), 2.15 (ddd, *J* = 15.1, 10.9, 5.2 Hz, 1H), 1.99 – 1.93 (m, 4H), 1.75 – 1.68 (m, 1H), 1.71 (s, 4H), 1.63 (bs, 1H), 1.60 (s, 3H), 1.37 – 1.23 (m, 7H), 0.95 (s, 3H), 0.87 (t, *J* = 7.0 Hz, 3H), 0.82 (s, 3H); ¹³C {¹H} NMR (151 MHz, CDCl₃): δ 137.1 (C), 135.0 (C), 125.3 (CH), 118.2 (CH), 75.0 (CH), 48.8 (CH), 42.0 (CH₂), 38.1 (C), 31.8 (CH₂), 31.6 (CH₂), 29.5 (CH₂), 27.9 (CH₂), 27.2 (CH₂), 27.0

(CH), 25.3 (CH₃), 22.6 (CH₃), 16.2 (CH₃), 16.0 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) m/z: [M + H]⁺

Calcd for C₁₉H₃₅O 279.2688, Found 279.2690.

(1*S*,3*R*)-2,2-Dimethyl-4-methylene-3-((*E*)-3-methylnon-3-en-1-yl)cyclohexan-1-ol (**7b**). A fraction enriched in **7b** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 22.6 min) to give pure **7b**. Colourless oil. ¹H NMR (600 MHz, CDCl₃): δ 5.10 (t, *J* = 7.3 Hz, 1H), 4.88 (s, 1H), 4.61 (s, 1H), 3.41 (dd, *J* = 9.9, 4.2 Hz, 1H), 2.33 (dt, *J* = 13.2, 4.8 Hz, 1H), 2.08 (ddd, *J* = 13.6, 9.6, 4.2 Hz, 2H), 2.02–1.94 (m, 3H), 1.88 – 1.77 (m, 2H), 1.67 – 1.46 (m, 4H), 1.59 (s, 3H), 1.35 – 1.24 (m, 6H), 1.03 (s, 3H), 0.89 (t, *J* = 6.9 Hz, 3H), 0.72 (s, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃): δ 149.9 (C), 137.7 (C), 127.6 (CH), 111.0 (CH₂), 80.0 (CH), 53.4 (CH), 43.2 (C), 41.2 (CH₂), 35.8 (CH₂), 34.9 (CH₂), 34.2 (CH₂), 32.2 (CH₂), 30.5 (CH₂), 28.5 (CH₃), 26.3 (CH₂), 25.3 (CH₂), 18.6 (CH₃), 18.1 (CH₃), 16.8 (CH₃); HRMS (ESI-QTOF) m/z: [M – OH]⁺ Calcd for C₁₉H₃₃ 261.2582, Found 261.2578.

Using benzene as solvent

Following the general procedure, reaction of epoxide **2** with Et₂AlCl, using benzene as a solvent at 10°C for 45 minutes provided after flash chromatography (H:MTBE, 9:1) compounds **3a** and **3b** (54%, 1:0.8 ratio), compound **4** (2%) and compound **5** (3%). Ratios were determined by integration of the ¹H NMR spectrum of the mixture.

(2*R*,3*S*,4*R*)-2,3,4-Trimethyl-3-((*E*)-3-methylnon-3-en-1-yl)cyclohexan-1-one (**5**). Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.16 (t, *J* = 7.1 Hz, 1H), 2.50 (q, *J* = 6.7 Hz, 1H), 2.37 – 2.33 (m, 2H), 2.14 – 1.80 (m, 6H), 1.68 – 1.55 (m, 1H), 1.63 (s, 3H), 1.48 – 1.23 (m, 8H), 0.94 (d, *J* = 6.7 Hz, 3H), 0.91 (d, *J* = 10.2 Hz, 3H), 0.91 (t, *J* = 3.5 Hz, 3H), 0.59 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃) δ 214.1 (C), 134.8 (C), 124.9 (CH₂), 50.5 (CH), 43.5 (C), 41.6 (CH₂), 36.1(CH), 36.0 (CH₂), 32.6 (CH₂), 31.6 (CH₂), 31.0(CH₂), 29.5(CH₂), 28.0 (CH₂), 22.6 (CH₂), 16.2 (CH₃), 15.4 (CH₃), 15.0 (CH₃), 14.1 (CH₃), 7.6 (CH₃); HRMS (ESI-QTOF) m/z: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688, Found 279.2687.

Using THF as solvent

Following the general procedure, reaction of epoxide **2** with Et₂AlCl, using THF as a solvent for 1 h provided after flash chromatography (H:MTBE, 9:1) in silica column compounds **6** and **4** (4%, 1:1 ratio), compounds **7a** and **7b** (4%, 1:1.3 ratio) and compound **10** (91%). Ratios were determined by integration of the ¹H NMR spectrum of the mixture.

(6*E*,10*E*)-2,6,10-Trimethylhexadeca-6,10-dien-3-one (**10**). Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.15 – 5.10 (m, 1H), 2.61 (hept, *J* = 6.9 Hz, 1H), 2.56 – 2.51 (m, 2H), 2.24 (t, *J* = 7.8 Hz, 2H), 2.08 (q, *J* = 7.3 Hz, 2H), 2.01 – 1.94 (m, 2H), 1.37 – 1.24 (m, 6H), 1.60 (d, *J* = 8.0 Hz, 6H), 0.89 (t, *J* = 7.0 Hz, 3H); ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 135.0 (C), 133.8 (C), 125.0 (CH), 88.7 (C), 86.0 (CH), 55.1 (CH), 45.2 (C), 39.8 (CH₂), 39.0 (CH₂), 31.5 (CH₂), 29.5 (CH₂), 27.8 (CH₂), 26.1 (CH₂), 26.1 (CH₃), 25.7 (CH₂), 23.9 (CH₃), 22.6 (CH₂), 18.9 (CH₃), 15.9 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688; Found 279.2706.

Using CH₃CN as solvent

Following the general procedure, reaction of epoxide **2** with Et₂AlCl, using acetonitrile as a solvent at -40 °C for 1 h provided after chromatography in silica column, using mixtures of H and MTBE of increasing polarity, compound **8a** (H:MTBE, 95:5, 22%) and compound **11** (H:MTBE, 2:1, 43%). Ratios were determined by integration of the ¹H NMR spectrum of the mixture.

(2*S*,4*aS*,8*aR*)-1,1,4*a*,6-tetramethyl-5-pentyl-1,2,3,4,4*a*,7,8,8*a*-octahydronaphthalen-2-ol (**8a**). A fraction enriched in **8a** was subjected to HPLC (normal phase, H:TBME 5:1, *R*_t = 13.1 min) to give pure **8a**. Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 3.25 (dd, *J* = 11.7, 4.7 Hz, 1H), 2.10 – 1.94 (m, 3H), 1.88 – 1.81 (m, 2H), 1.75 – 1.56 (m, 3H), 1.57 (s, 3H), 1.46 (ddd, *J* = 24.4, 12.4, 6.3 Hz, 1H), 1.38 – 1.24 (m, 6H), 1.11 (dd, *J* = 12.4, 2.0 Hz, 1H), 1.01 (s, 3H), 0.95 (s, 3H), 0.90 (t, *J* = 7.0 Hz, 3H), 0.81 (s, 3H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 140.5 (C), 125.6 (C), 79.0 (CH), 51.1 (CH), 38.8 (C), 38.7 (C), 35.0 (CH₂), 33.8 (CH₂), 32.8 (CH₂), 30.4 (CH₂), 28.2 (CH₂), 28.1 (CH₃), 27.8 (CH₂), 22.5 (CH₂),

20.1 (CH₃), 19.4 (CH₃), 18.8 (CH₂), 15.5 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) m/z: [M - OH]⁺
Calcd for C₁₉H₃₃ 261.2582, Found 261.2584. A fraction enriched in **8a** was subjected to HPLC (normal
phase, H:TBME 5:1, Rt = 13.1 min) to give pure **8a**. Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 3.25
(dd, *J* = 11.7, 4.7 Hz, 1H), 2.10–1.94 (m, 3H), 1.88 – 1.81 (m, 2H), 1.75 – 1.56 (m, 3H), 1.57 (s, 3H),
1.46 (ddd, *J* = 24.4, 12.4, 6.3 Hz, 1H), 1.38 – 1.24 (m, 6H), 1.11 (dd, *J* = 12.4, 2.0 Hz, 1H), 1.01 (s, 3H),
0.95 (s, 3H), 0.90 (t, *J* = 7.0 Hz, 3H), 0.81 (s, 3H); ¹³C {¹H} NMR (126 MHz, CDCl₃): δ 140.5 (C),
125.6 (C), 79.0 (CH), 51.1 (CH), 38.8 (C), 38.7 (C), 35.0 (CH₂), 33.8 (CH₂), 32.8 (CH₂), 30.4 (CH₂),
28.2 (CH₂), 28.1 (CH₃), 27.8 (CH₂), 22.5 (CH₂), 20.1 (CH₃), 19.4 (CH₃), 18.8 (CH₂), 15.5 (CH₃), 14.1
(CH₃); HRMS (ESI-QTOF) m/z: [M - OH]⁺ Calcd for C₁₉H₃₃ 261.2582, Found 261.2584.

N-((6*E*,10*E*)-3-hydroxy-2,6,10-trimethylhexadeca-6,10-dien-2-yl)acetamide (**11**). Colourless oil. ¹H
NMR (500 MHz, CDCl₃): δ 5.17 (t, *J* = 6.9 Hz, 1H), 5.14 (t, *J* = 7.1 Hz, 1H), 4.01 (dd, *J* = 9.9, 3.7 Hz,
1H), 2.24 – 1.93 (m, 8H), 1.98 (s, 3H), 1.73 – 1.56 (m, 2H), 1.63 (s, 3H), 1.60 (s, 3H), 1.37 – 1.24 (m,
6H), 1.28 (s, 3H), 1.12 (s, 3H), 0.89 (t, *J* = 7.0 Hz, 3H); ¹³C {¹H} NMR (125 MHz, CDCl₃): δ 163.9 (C),
134.6 (C), 133.8 (C), 125.1 (CH), 125.0 (CH), 88.7 (CH), 66.6 (C), 39.6 (CH₂), 36.7 (CH₂), 31.6 (CH₂),
29.6 (CH₂), 29.1 (CH₃), 28.6 (CH₂), 27.9 (CH₂), 26.6 (CH₂), 22.8 (CH₃), 22.6 (CH₂), 16.0 (CH₃), 15.9
(CH₃), 14.3 (CH₃), 14.1 (CH₃); HRMS (ESI-QTOF) m/z: [M - OH]⁺ Calcd for C₂₁H₃₈NO 320.2983,
Found 320.2953.

Cyclization of epoxypolyprene **12**

Following the general procedure, reaction of epoxide **12** with Et₂AlCl for 1 h provided a mixture which
was a complex mixture of drimanes structures, in good agreement with the results described by Corey *et*
*al.*¹³

Cyclization of epoxyolyprene 13

Following the general procedure, reaction of epoxide **13** with Et₂AlCl for 1 h provided after flash chromatography (H:MTBE, 6:1) compounds **14a** and **14b** (30% combined, 1:2 ratio). Ratios were determined by integration of the ¹H spectrum of the mixture.

(2*S*,4*aS*,5*R*,6*R*)-5-(3-((*Tert*-butyldimethylsilyl)oxy)butyl)-1,1,5,6-tetramethyl-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**14b**). Compound **14b** was purified and characterized as its alcohol derivative **14b'**. A fraction enriched in **14b** was desilylated with TBAF (3 equiv) for 13 h and the resulting crude subjected to HPLC (normal phase, H:MTBE 1:1, Rt = 21.1 min) to give pure **14b'**. Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.46 (t, *J* = 3.9 Hz, 1H), 3.72 (dq, *J* = 11.9, 6.0 Hz, 1H), 3.44 (m, 1H), 2.20 – 2.00 (m, 2H), 1.91 (tdd, *J* = 14.0, 4.4, 2.5 Hz, 1H), 1.79 – 1.12 (m, 9H), 1.20 (d, *J* = 6.2 Hz, 3H), 1.13 (s, 6H), 0.83 (s, 3H), 0.80 (d, *J* = 6.8 Hz, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃): only distinguishable signals δ 76.8 (CH), 69.1 (CH), 40.0 (CH), 35.8 (CH), 33.3 (CH₂), 32.8 (CH₃), 23.6 (CH₃), 22.2 (CH₃), 14.6 (CH₃). HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₁₈H₃₃O₂ 281.2481, Found 281.2462.

Cyclization of epoxyolyprene 15

Following the general procedure, reaction of epoxide **15** with Et₂AlCl for 1 h provided after flash chromatography (H:TBME, 6:1) compounds **16a** and **16b** (55% combined, 1:1.2 ratio). Ratios were determined by integration of the ¹H spectrum of the mixture. These two compounds were produced as a mixture of epimers at C-13).

(2*S*,4*aS*,5*R*,6*S*)-1,1,5,6-Tetramethyl-5-(3-methylpent-4-en-1-yl)-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**16a**). A fraction enriched in **16a** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 37.8 min) to give pure **16a**. Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.74-5.66 (m, 1H), 5.54 (m, 1H), 4.99 – 4.91 (m, 2H), 3.48 – 3.47 (m, 1H), 2.22 (m, 1H), 2.06 – 1.99 (m, 1H), 1.90 – 1.68 (m, 4H), 1.54-1.49 (m, 3H), 1.37-1.20 (m 4H), 1.14 (s, 3H), 1.06 (s, 3H), 1.02 (d, *J* = 6.7 Hz, 3H), 0.82 (d, *J* = 6.8 Hz, 3H) (epimer I), (0.81, d, *J* = 6.8 Hz, 3H) (epimer II), 0.66 (s, 3H); ¹³C {¹H} NMR (75 MHz, CDCl₃): δ 144.9 (CH) (epimer I), 144.8 (CH) (epimer II), 142.4 (C) (epimer I), 142.3 (C) (epimer II), 120.8 (CH)

(epimer II), 120.8 (CH) (epimer I), 112.6 (CH₂) (epimer II), 112.6 (CH₂) (epimer I), 76.4 (CH), 41.3 (C), 38.7 (CH) (epimer II), 38.7 (CH) (epimer I), 38.6 (CH) (epimer II), 38.5 (CH) (epimer I), 37.0 (C) (epimer II), 36.9 (C) (epimer I), 34.1 (CH₂), 33.4 (CH) (epimer I), 33.4 (CH) (epimer II), 31.9 (CH₂), 29.5 (CH₂), 28.4 (CH₃), 28.3 (CH₂), 25.6 (CH₃), 20.3 (CH₃) (epimer II), 20.3 (CH₃) (epimer I), 19.8 (CH₂) (epimer II), 19.8 (CH₂) (epimer I), 16.3 (CH₃), 15.0 (CH₃); HRMS (ESI-QTOF) m/z: [M – OH]⁺ Calcd for C₂₀H₃₃ 273.2582, Found 273.2589.

(2*S*,4*aS*,5*R*,6*R*)-1,1,5,6-Tetramethyl-5-(3-methylpent-4-en-1-yl)-1,2,3,4,4*a*,5,6,7-octahydro naphthalen-2-ol (**16b**). A fraction enriched in **16b** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 38.9 min) to give pure **16b**. Colourless oil. ¹H NMR (500 MHz, DMSO-D₆, 78 °C): δ 5.76–5.67 (m, 1H), 5.29 – 5.26 (m, 1H), 4.97 – 4.88 (m, 2H), 3.32 (t, *J* = 3.1 Hz, 1H), 2.11–1.94 (m, 3H), 1.87 – 1.79 (m, 1H), 1.68 – 1.39 (m, 5H), 1.36 – 1.11 (m 3H), 1.02 (s, 3H), 0.98 (s, 3H), 0.97 (d, *J* = 4.9 Hz, 3H) (epimer I), 0.95 (d, *J* = 4.9 Hz, 3H) (epimer II), 0.78 (s, 3H) (epimer I), 0.77 (s, 3H) (epimer II), 0.76 (d, *J* = 6.6 Hz, 3H) (epimer I), 0.74 (d, *J* = 6.6 Hz, 3H) (epimer II); ¹³C{¹H} NMR (125 MHz DMSO–D₆): δ 149.9 (CH) 121.5 (CH), 117.7 (CH₂) (epimer I), 117.6 (CH₂) (epimer II), 80.1 (CH), 46.3 (C), 45.0 (CH), 43.0 (CH) (epimer I), 42.9 (CH) (epimer II), 40.8 (C) 37.7 (CH) (epimer I), 37.7 (CH) (epimer II), 35.9 (CH₂), 35.0 (CH₂), 34.6 (CH₂), 32.3 (CH₃), 30.2 (CH₃), 26.9 (CH₃) (epimer I), 26.89 (CH₃) (epimer II), 26.6 (CH₂) 25.1 (CH₃), 19.6 (CH₃) (epimer I), 19.61 (CH₃) (epimer II); HRMS (ESI-QTOF) m/z: [M – OH]⁺ Calcd for C₂₀H₃₃ 273.2582, Found 273.2589.

Cyclization of epoxyolyprene 17

Following the general procedure, reaction of epoxide **17** with Et₂AlCl for 30 min provided after flash chromatography (H:MTBE, 9:1) compounds **18a** and **18b** (75% combined, 1:1 ratio). Ratios were determined by integration of the ¹H spectrum of the mixture.

(2*S*,4*aS*,5*R*,6*S*)-1,1,5,6-Tetramethyl-5-(2-((4*aS*,8*aR*)-2,4*a*,7,7-tetramethyl-3,4,4*a*,5,6,7,8,8*a*-octahydronaphthalen-1-yl)ethyl)-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**18a**). A fraction enriched

in **18a** subjected to HPLC (normal phase, H:TBME 6:1, Rt = 18.9 min) to give pure **18a**. Colourless oil.

^1H NMR (500 MHz, CDCl_3): δ 5.55 (m, 1H), 3.48 (t, $J = 2.9$ Hz, 1H), 2.22 (bd, $J = 12.1$ Hz, 1H), 2.12 (dt, $J = 13.1, 8.4$ Hz, 1H), 2.01 – 1.66 (m, 8H), 1.62 – 1.44 (m, 6H), 1.56 (s, 3H), 1.40 – 0.96 (m, 7H), 1.14 (s, 3H), 1.08 (s, 3H), 0.89 (s, 3H), 0.89 (d, $J = 6.7$ Hz, 3H), 0.89 (s, 3H), 0.83 (s, 3H), 0.67 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 142.5 (C), 133.8 (C), 123.5 (C), 120.9 (CH), 76.5 (CH), 43.2 (CH₂), 42.5 (CH), 41.5 (C), 38.6 (CH), 37.1 (C), 36.6 (CH₂), 35.2 (CH₂), 34.6 (CH₂), 33.6 (CH), 33.2 (CH₃), 31.9 (CH₂), 31.5 (C), 31.1 (C), 29.6 (CH₂), 28.5 (CH₂), 28.5 (CH₃), 27.1 (CH₃), 26.6 (CH₂), 25.6 (CH₃), 24.7 (CH₂), 24.2 (CH₃), 20.4 (CH₂), 18.6 (CH₃), 16.3 (CH₃), 15.4 (CH₃); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OH}]^+$ Calcd for $\text{C}_{30}\text{H}_{49}$ 409.3834, Found 409.3829.

(2*S*,4*aS*,5*R*,6*R*)-1,1,5,6-Tetramethyl-5-(2-((4*aS*,8*aR*)-2,4*a*,7,7-tetramethyl-3,4,4*a*,5,6,7,8,8*a*-octahydronaphthalen-1-yl)ethyl)-1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**18b**). A fraction enriched in **18b** subjected to HPLC (normal phase, H:MTBE 6:1, Rt = 20.2 min) to give pure **18b**. Colourless oil.

^1H NMR (500 MHz, CDCl_3): only distinguishable signals δ 5.46 (t, $J = 3.8$ Hz, 1H), 3.45 (m, 1H), 2.12 (m, 1H), 2.06 (dt, $J = 12.6, 4.9$ Hz, 1H), 2.00 – 1.80 (m, 7H), 1.77 – 1.64 (m, 3H), 1.61 – 0.92 (m, 10H), 1.51 (s, 3H), 1.10 (m, 3H), 0.89 (m, 3H), 0.88 (m, 9H), 0.82 (m, 3H), 0.81 (m, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): only distinguishable signals δ 134.0 (C), 123.2 (C), 120.7 (CH), 76.6 (CH), 43.1 (CH₂), 42.5 (CH), 39.9 (CH), 36.5 (CH₂), 35.9 (C), 34.6 (CH₂), 33.1 (CH₃), 32.7 (CH), 31.5 (CH₂), 31.0 (C), 29.4 (CH₂), 29.2 (CH₂), 26.9 (CH₃), 26.5 (CH₂), 25.1 (CH₂), 24.8 (CH₃), 24.1 (CH₃), 22.6 (CH₂), 22.2 (CH₃), 18.3 (CH₃), 14.5 (CH₃), 14.1 (CH₃); HRMS (FAB) m/z : $[\text{M} - \text{OH}]^+$ Calcd for $\text{C}_{30}\text{H}_{49}$ 409.3834, Found 409.3831.

Cyclization of epoxy polyprene **19**

Following the general procedure, reaction of epoxide **13** with Et_2AlCl for 50 min provided after flash chromatography (H:MTBE, 4:1) compound **21** (5.5%) and compounds **20a** and **20b** (32%, 1:9 ratio).

Ratios were determined by integration of the ^1H spectrum of the mixture.

Methyl (2E,6E)-3,7-dimethyl-9-((1S,2R,6R)-1,2,6-trimethyl-3-oxocyclohexyl)nona-2,6-dienoate (21).

A fraction enriched in **21** was subjected to HPLC (normal phase, H:MTBE 6:1, $R_t = 20.9$ min) to give pure **21**. Colourless oil. ^1H NMR (500 MHz, CDCl_3): δ 5.68 (bs, 1H), 5.14 – 5.08 (m, 1H), 3.70 (s, 3H), 2.49 (q, $J = 6.7$ Hz, 1H), 2.37 – 2.33 (m, 2H), 2.20 – 2.16 (m, 7H), 2.06 – 1.97 (m, 2H), 1.90 – 1.81 (m, 2H), 1.67 – 1.60 (m, 1H), 1.64 (s, 3H), 1.43 (ddd, $J = 14.6, 12.4, 4.8$ Hz, 1H), 1.36 (ddd, $J = 14.4, 13.0, 4.4$ Hz, 1H), 0.94 (d, $J = 6.7$ Hz, 3H), 0.91 (d, $J = 6.8$ Hz, 3H), 0.59 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 213.9 (C), 167.2 (C), 159.9 (C), 136.4 (C), 122.9 (CH), 115.4 (CH), 50.8 (CH_3), 50.5 (CH), 43.4 (C), 41.6 (CH_2), 40.9 (CH_2), 32.7 (CH), 29.3 (CH_2), 24.6(CH_3), 22.2 (CH_3), 19.1 (CH_3), 14.5 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{21}\text{H}_{34}\text{O}_3$ 334.2508, Found 334.2513.

Methyl (E)-5-((1R,2R,6S,8aS)-6-hydroxy-1,2,5,5-tetramethyl-1,2,3,5,6,7,8,8a-octahydronaphthalen-1-yl)-3-methylpent-2-enoate (20b). A fraction enriched in **20b** was subjected to HPLC (normal phase, H:MTBE 4:1, $R_t = 26.5$ min) to give pure **20b**. Colourless oil. ^1H NMR (600 MHz, CDCl_3): only distinguishable signals δ 5.66 (bs, 1H), 5.45 (t, $J = 3.3$ Hz, 1H), 3.68 (s, 3H), 3.45 (bs, 1H), 2.15 (s, 3H), 2.13 – 1.98 (m, 3H), 1.91 (tdd, $J = 14.1, 4.7, 2.6$ Hz, 1H), 1.77 – 1.64 (m, 3H), 1.70 – 1.29 (m, 4H), 1.10 (s, 6H), 0.81 (d, $J = 6.7$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): only distinguishable signals δ 167.3 (C), 161.7 (C), 120.7 (CH), 114.9 (CH), 76.5 (CH), 50.8 (CH_3), 40.0 (CH), 35.3 (CH_2), 32.7 (CH), 29.3 (CH_2), 24.6 (CH_3), 22.2 (CH_3), 19.1 (CH_3), 14.5 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OH}]^+$ Calcd for $\text{C}_{21}\text{H}_{33}\text{O}_2$ 317.2481, Found 317.2486.

Cyclization of epoxyolyprene **22**

Following the general procedure, reaction of epoxide **22** with Et_2AlCl for 40 min provided after flash chromatography (H:MTBE, 2:1) compound **23a** and **23b** (12%, 1:9 ratio). Ratios were determined by integration of the ^1H spectrum of the mixture.

(2S,4aS,5R,6R)-5-(3-Hydroxy-3-methylpent-4-en-1-yl)-1,1,5,6-tetramethyl-1,2,3,4,4a,5,6,7-octahydronaphthalen-2-ol (23b). Colourless oil. ^1H NMR (600 MHz, CDCl_3): only distinguishable

1 signals δ 5.87 (dd, $J = 17.4, 10.7$ Hz, 1H), 5.44 (t, $J = 3.3$ Hz, 1H), 5.18 (dd, $J = 17.3, 1.2$ Hz, 1H), 5.04
2 (dd, $J = 10.7, 1.2$ Hz, 1H), 3.43 (bs, 1H), 2.09 – 2.01 (m, 1H), 1.89 (tdd, $J = 13.9, 4.7, 2.6$ Hz, 1H), 1.71
3 (ddd, $J = 15.0, 7.2, 3.6$ Hz, 1H), 1.64 (dq, $J = 13.6, 6.6$ Hz, 1H), 1.50 – 1.32 (m, 3H), 1.40 (td, $J = 12.9,$
4 3.9 Hz, 1H), 1.26 (s, 3H), 1.09 (s, 3H), 1.08 (s, 3H), 0.80 (s, 3H), 0.78 (d, $J = 6.9$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$
5 NMR (150 MHz, CDCl_3): only distinguishable signals δ 145.2 (CH), 111.7 (CH_2), 76.5 (CH), 39.9
6 (CH), 36.0 (CH_2), 32.8 (CH), 29.3 (CH_2), 27.8 (CH_3), 24.7 (CH_3), 22.1 (CH_3), 14.6 (CH_3).
7
8
9
10
11
12
13
14
15
16

17 Cyclization of epoxyolyprene 24

18
19 Following the general procedure, reaction of epoxide **24** with Et_2AlCl for 50 min provided after
20 column chromatography aldehyde **26** (H:MTBE, 5:1) (4%), compound **27** (H:MTBE, 5:1) (6%) and
21 compounds **25a** and **25b** (H:MTBE, 4:1) (53% combined, 1:2.5 ratio). Compounds **25a** and **25b** were
22 obtained as a pair of diastereomers. **25a1** and **25a2**, and **25b1** and **25b2**, respectively.
23
24
25
26
27

28 *Compound 25a1.* A mixture of **25a** and **25b** was subjected to HPLC (normal phase, H:MTBE 9:1), to
29 give pure **25a1** ($R_t = 47.7$ min). Colourless oil. ^1H NMR (600 MHz, CDCl_3): δ 5.98 (dd, $J = 17.6, 11.0$
30 Hz, 1H), 5.52 (dt, $J = 5.0, 2.2$ Hz, 1H), 5.14 (dd, $J = 17.6, 0.9$ Hz, 1H), 5.12 (dd, $J = 11.0, 0.9$ Hz, 1H),
31 3.47 (t, $J = 2.9$ Hz, 1H), 2.22 – 2.17 (m, 1H), 2.00 (s, 3H), 1.91 – 1.83 (m, 2H), 1.81 – 1.66 (m, 4H),
32 1.52 (s, 3H), 1.51 – 1.42 (m, 3H), 1.38 – 1.31 (m, 1H), 1.25 (ddd, $J = 14.2, 11.6, 6.0$ Hz, 1H), 1.13 (s,
33 3H), 1.05 (s, 3H), 0.80 (d, $J = 6.7$ Hz, 3H), 0.66 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 169.9 (C),
34 142.2 (CH), 141.9 (C), 120.7 (CH), 113.1 (CH_2), 83.2 (C), 76.3 (CH), 41.3 (C), 38.5 (CH), 36.8 (C),
35 33.2 (CH), 32.8 (CH_2), 31.8 (CH_2), 29.6 (CH_2), 28.5 (CH_3), 28.2 (CH_2), 25.5 (CH_3), 23.7 (CH_3), 22.2
36 (CH_3), 19.8 (CH_2), 16.3 (CH_3), 14.9 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OAc}]^+$ Calcd for $\text{C}_{20}\text{H}_{33}\text{O}$
37 289.2537, Found 289.2518.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 *Compound 25a2.* A mixture of **25a** and **25b** was subjected to HPLC (normal phase, H:MTBE 9:1), to
52 give pure **25a2** ($R_t = 53.6$ min). Colourless oil. ^1H NMR (500 MHz, CDCl_3): δ 5.93 (dd, $J = 17.5, 11.0$
53 Hz, 1H), 5.52 (dt, $J = 5.9, 1.9$ Hz, 1H), 5.16 (dd, $J = 17.5, 1.0$ Hz, 1H), 5.12 (dd, $J = 11.0, 1.0$ Hz, 1H),
54
55
56
57
58
59
60

3.47 (t, $J = 3.0$ Hz, 1H), 2.23 – 2.17 (m, 1H), 2.01 (s, 3H), 1.91 – 1.75 (m, 4H), 1.71 – 1.57 (m, 2H),
1.54 (s, 3H), 1.54 – 1.43 (m, 3H), 1.33 (dt, $J = 13.5, 4.0$ Hz, 1H), 1.25 (ddd, $J = 14.4, 12.8, 4.9$ Hz, 1H),
1.13 (s, 3H), 1.06 (s, 3H), 0.80 (d, $J = 6.7$ Hz, 3H), 0.66 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ
169.9 (C), 142.2 (CH), 141.9 (C), 120.7 (CH), 113.1 (CH_2), 83.2 (C), 76.3 (CH), 41.3 (C), 38.5 (CH),
36.8 (C), 33.2 (CH), 32.8 (CH_2), 31.8 (CH_2), 29.6 (CH_2), 28.5 (CH_3), 28.2 (CH_2), 25.5 (CH_3), 23.7
(CH_3), 22.2 (CH_3), 19.8 (CH_2), 16.3 (CH_3), 14.9 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OAc}]^+$ Calcd for
 $\text{C}_{20}\text{H}_{33}\text{O}$ 289.2537, Found 289.2527.

Compound 25b1. A mixture of **25a** and **25b** was subjected to HPLC (normal phase, H:MTBE 9:1), to
give pure **25b1** ($R_t = 41.8$ min). Colourless oil. ^1H NMR (600 MHz, CDCl_3): only distinguishable
signals δ 5.92 (dd, $J = 17.5, 11.0$ Hz, 1H), 5.44 (t, $J = 3.7$ Hz, 1H), 5.12 (d, $J = 17.5$, 1H), 5.10 (d, $J =$
11.0 Hz, 1H), 3.43 (bs, 1H), 2.09 – 2.01 (m, 1H), 1.99 (s, 3H), 1.90 (tdd, $J = 13.9, 4.7, 2.4$ Hz, 1H), 1.81
(bt, $J = 13.0$ Hz, 1H), 1.75 – 1.68 (m, 1H), 1.67 – 1.60 (m, 2H), 1.51 (s, 3H), 1.09 (s, 3H), 1.08 (s, 3H),
0.80 (s, 3H), 0.77 (d, $J = 6.8$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): only distinguishable signals δ
169.8 (C), 141.9 (CH), 113.1 (CH_2), 76.5 (CH), 39.9 (CH), 33.6 (CH_2), 32.8 (CH), 29.2 (CH_2), 24.7
(CH_3), 23.6 (CH_3), 22.2 (CH_3), 22.0 (CH_3), 14.5 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OAc}]^+$ Calcd
for $\text{C}_{20}\text{H}_{33}\text{O}$ 289.2537, Found 289.2524.

Compound 25b2. A mixture of **25a** and **25b** was subjected to HPLC (normal phase, H:MTBE 9:1), to
give pure **25b2** ($R_t = 43.7$ min). Colourless oil. ^1H NMR (600 MHz, CDCl_3): only distinguishable
signals δ 5.95 (dd, $J = 17.5, 11.0$ Hz, 1H), 5.45 (t, $J = 3.5$ Hz, 1H), 5.13 (d, $J = 17.6$, 1H), 5.10 (dd, $J =$
11.1, 1H), 3.44 (bs, 1H), 2.07 – 2.01 (m, 1H), 1.98 (s, 3H), 1.91 (tdd, $J = 14.0, 4.5, 2.5$ Hz, 1H), 1.75 –
1.68 (m, 3H), 1.64 (dq, $J = 14.1, 7.4$ Hz, 1H), 1.50 (s, 3H), 1.09 (s, 6H), 0.80 (s, 3H), 0.77 (d, $J = 6.6$ Hz,
3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): only distinguishable signals δ 169.8 (C), 142.0 (CH), 113.1
(CH_2), 76.5 (CH), 39.8 (CH), 33.6 (CH_2), 32.8 (CH), 29.3 (CH_2), 24.8 (CH_3), 23.6 (CH_3), 22.2 (CH_3),
22.0 (CH_3), 14.5 (CH_3); HRMS (ESI-QTOF) m/z : $[\text{M} - \text{OAc}]^+$ Calcd for $\text{C}_{20}\text{H}_{33}\text{O}$ 289.2537, Found
289.2530.

(E)-3,7,11-Trimethyl-13-oxo-10-(propan-2-ylidene)trideca-1,6-dien-3-yl acetate (**26**). Aldehyde **26** was purified and characterized as its primary alcohol derivative **26a**. To a solution of a fraction enriched in **26** (44 mg) in 22 mL of MeOH:H₂O (4:1 ratio) was added 15 mg of NaBH₄ and the mixture was stirred for 30 min at 0°C. The reaction was concentrated under reduced pressure and the residue dissolved in MTBE and washed with water, quenched with acetone, and concentrated under reduced pressure. The organic layer was washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The resulting crude was purified by column chromatography (H/MTBE, 3:1) to afford 21 mg of primary alcohol **26a**. Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.99 (dd, *J* = 17.5, 11.0 Hz, 1H), 5.17 (dd, *J* = 17.6, 1.0 Hz, 1H), 5.13 (dd, *J* = 11.0, 0.9 Hz, 1H), 5.15–5.10 (m, 1H), 3.62 (t, *J* = 6.6 Hz, 2H), 2.71 (sext, *J* = 7.1 Hz, 1H), 2.06 – 1.85 (m, 7H), 2.02 (s, 3H), 1.82–1.76 (m, 2H), 1.82 – 1.76 (m, 2H), 1.68 (s, 3H), 1.66 (s, 3H), 1.63 (s, 3H), 1.56 (s, 3H), 1.38 – 1.32 (m, 2 H), 0.97 (d, *J* = 6.9 Hz, 3H); ¹³C{¹H} NMR (75 MHz, CDCl₃): δ 170.0 (C), 141.8 (CH), 136.3 (C), 135.5 (C), 125.3 (C), 123.1 (CH), 113.1 (CH₂), 82.9 (C), 63.4 (CH₂), 40.2 (CH₂), 39.8 (CH₂), 35.6 (CH), 31.6 (CH₂), 31.2 (CH₂), 26.8 (CH₂), 23.6 (CH₃), 22.2 (CH₂), 22.2 (CH₃), 20.9 (CH₃), 20.1 (CH₃), 19.6 (CH₃), 16.0 (CH₃); HRMS (ESI-QTOF) *m/z*: [M – OAc]⁺ Calcd for C₂₀H₃₅O 291.2693, Found 291.2693.

(E)-3,7-Dimethyl-9-((1*S*,2*R*,6*R*)-1,2,6-trimethyl-3-oxocyclohexyl)nona-1,6-dien-3-yl acetate (**27**). Colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 5.99 (dd, *J* = 17.5, 11.0 Hz, 1H), 5.17 (dd, *J* = 17.5, 1.0 Hz, 1H), 5.14 (dd, *J* = 11.0, 0.8 Hz, 1H), 5.15 – 5.10 (m, 1H), 2.49 (q, *J* = 6.7 Hz, 1H), 2.38 – 2.33 (m, 2H), 2.05 – 1.95 (m, 4H), 2.02 (s, 3H), 1.91 – 1.75 (m, 4H), 1.67 – 1.58 (m, 1H), 1.62 (s, 3H), 1.55 (s, 3H), 1.46 – 1.32 (m, 2H), 0.94 (d, *J* = 6.7 Hz, 3H), 0.91 (d, *J* = 6.7 Hz, 3H), 0.59 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 213.9 (C), 169.9 (C), 141.8 (CH), 135.5 (C), 123.8 (CH), 113.1 (CH₂), 82.9 (C), 50.5 (CH), 43.4 (C), 41.6 (CH₂), 39.7 (CH₂), 36.1 (CH), 35.9 (CH₂), 32.5 (CH₂), 31.0 (CH₂), 23.6 (CH₃), 22.3 (CH₂), 22.2 (CH₃), 16.1 (CH₃), 15.4 (CH₃), 15.0 (CH₃), 7.6 (CH₃); HRMS (ESI-QTOF) *m/z*: [M – OAc]⁺ Calcd for C₂₀H₃₃O 289.2537, Found 289.2533.

Cyclization of epoxypropene 2 using Br₃In as Lewis acid

To a solution of starting material (0.5 mmol) in dry DCM (10 mL) was added indium tribromide (0.5 mmol) at room temperature. The reaction mixture was further stirred until disappearance of the starting material. Then, solvent was removed under reduced pressure and the crude reaction mixture passed through a short plug of silica gel and celite (4:1) which was washed with EtOAc:H (9:1). Finally the crude resultant was concentrated under reduced pressure and then purified by flash chromatography in silica column (H:MTBE, 95:5), to obtain compounds **3a** and **3b** (37%, 1:0.45 ratio), compound **4** (7%), compounds **7a** and **7b** (9%, 1:0.2 ratio), compounds **8b** and **8c** (9%, 1:0.8 ratio) and compounds **9a** and **9b** (25%, 1:0.7 ratio).

(2*S*,5*R*,6*S*,8*aR*)-1,1,5,6-Tetramethyl-5-pentyl-1,2,3,5,6,7,8,8a-octahydronaphthalen-2-ol (**9a**). A fraction enriched in **9a** was subjected to HPLC (normal phase, H:MTBE 9:1, Rt = 13.4 min) to give **9a** together with some proportion of **3a**. Colourless oil. ¹H NMR (600 MHz, CDCl₃): δ 5.28 (t, *J* = 4.0 Hz, 1H), 3.40 (dd, *J* = 6.2, 4.9 Hz, 1H), 2.33 (dtd, *J* = 17.5, 4.6, 2.0 Hz, 1H), 2.10 (dddd, *J* = 17.5, 5.9, 3.6, 2.1 Hz, 1H), 1.88 – 1.79 (m, 1H), 1.71 (d, *J* = 13.5 Hz, 1H), 1.57 – 1.36 (m, 3H), 1.37 – 1.15 (m, 8H), 1.05 – 0.98 (m, 1H), 1.00 (s, 3H), 0.91 (s, 3H), 0.87 (s, 3H), 0.86 (t, *J* = 7.3 Hz, 3H), 0.86 (d, *J* = 6.8 Hz, 3H); ¹³C {¹H} NMR (150 MHz, CDCl₃): δ 145.1 (C), 113.9 (CH), 74.9 (CH), 43.9 (CH), 43.1 (CH), 42.3 (C), 36.5 (C), 32.8 (CH₂), 31.5 (CH₂), 30.7 (CH₂), 29.1 (CH₂), 26.6 (CH₃), 23.2 (CH₂), 22.7 (CH₃), 22.7 (CH₂), 19.3 (CH₃), 16.5 (CH₃), 14.2 (CH₃); HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₁₉H₃₅O 279.2688, Found 279.2679.

Catalytic assays of cyclization plus rearrangement of epoxide 2

Using Et₂AlCl as Lewis acid

The reactions were performed following the general procedure and only varying the quantity of catalyst.

Using indium or gallium halides as Lewis acids

To a solution of starting material (0.5 mmol) in dry DCM (15 mL) was added the Lewis acid (0.2-0.01 mmol) at room temperature. The reaction mixture was further stirred until disappearance of the starting material. Then, solvent was removed under reduced pressure and the crude reaction mixture passed through a short plug of silica gel and celite (4:1) which was washed with MTBE. Finally the crude resultant was concentrated under reduced pressure and then column chromatographed to afford the corresponding mixtures of **3a** and **3b** (H:MTBE, 6:1).

Synthesis of isotuberculosinol (**1**)

A solution of 110 mg (0.31 mmol) of **25a** and **25b** in 3 mL of DCM was treated with 0.09 mL (0.62 mmol) of pentafluorophenyl chlorothionoformate (0.153 mmol) and 115 mg (0.9 mmol) of DMAP. After stirring for 7h at rt, the mixture was concentrated under vacuum and column chromatographed (H:MTBE, 20:1) to afford 151 mg of the corresponding xanthates. To a solution of 88 mg (0.15 mmol) of this mixture in 5 mL of degassed toluene, 9 mg of AIBN and 0.24 mL of tributyltin hydride (0.92 mmol) were added. The mixture was refluxed for 1h and then column chromatographed (H:MTBE, 15:1) to afford 85 mg of a mixture of deoxygenated products. This mixture was dissolved in 2 mL of THF and treated at rt with 38 mg of LAH at 0°C. The mixture was then stirred for 12 h. After the usual work-up, 58 mg (0.20 mmol) of a mixture of **1** and **1b** (1:2.5 ratio) were obtained (65%). This mixture was subjected to HPLC (normal phase H:MTBE, 10:1) to give **1** (Rt = 24.3 min) and **1b** (Rt = 26.1 min). Compounds **1** and **1b** were obtained both as a pair of diastereomers.

Isotuberculosinol (1). Colourless oil. ^1H NMR (600 MHz, CDCl_3): δ 5.92 (dd, $J = 17.4, 10.8$ Hz, 2H), 5.43 (bd, $J = 5.5$ Hz, 2H), 5.22 (bd, $J = 17.3$ Hz, 2H), 5.07 (bd, $J = 10.8$ Hz, 2H), 2.13 (dm, $J = 13.1$ Hz, 2H), 1.83 (dt, $J = 17.7, 5.5$ Hz, 2H), 1.74 – 1.68 (m, 4H), 1.60 – 1.33 (m, 14H), 1.30 (s, 6H), 1.29 – 1.17 (m, 4H), 1.06 (s, 6H), 1.01 (qd, $J = 12.9, 4.2$ Hz, 2H), 1.00 (s, 6H), 0.80 (d, $J = 6.8$ Hz, 3H), 0.79 (d, $J = 6.7$ Hz, 3H), 0.62 (s, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3): δ 146.0, 146.0 (C), 145.1, 145.1 (CH),

116.2, 116.1 (CH), 111.8, 111.8 (CH₂), 73.5, 73.3 (C), 40.9 (CH₂), 39.7 (CH), 36.7 (C), 36.1 (C), 35.2, 35.1 (CH₂), 33.3 (CH), 31.7 (CH₂), 30.1 (CH₂), 29.8 (CH₃), 29.1 (CH₃), 27.7, 27.6 (CH₃), 27.3 (CH₂), 22.2 (CH₂), 16.2, 16.2 (CH₃), 15.0, 15.0 (CH₃).

8-Epi-isotuberculosinol (1b). Colourless oil. ¹H NMR (600 MHz, CDCl₃): only distinguishable signals δ 5.91 (ddd, *J* = 17.4, 10.8, 6.9 Hz, 1H), 5.33 (bs, 1H), 5.21 (dd, *J* = 17.1, 2.9 Hz, 1H), 5.05 (d, *J* = 10.8 Hz, 1H), 1.96 (bd, *J* = 12.9 Hz, 1H), 1.79 – 1.00 (m, 14H), 1.28 (s, 3H), 1.05 (s, 3H), 1.02 (s, 3H), 0.79 (s, 3H), 0.77 (m, 3H); ¹³C {¹H} NMR (150 MHz, CDCl₃): only distinguishable signals δ 145.3, 145.3 (CH), 114.3 (CH), 111.7, 111.6 (CH₂), 73.5, 73.5 (C), 41.9 (CH₂), 40.8, 40.8 (CH), 36.0 (CH₂), 32.9, 32.9 (CH), 29.5 (CH₃), 27.7 (CH₃), 23.0 (CH₂), 22.0 (CH₃), 14.6 (CH₃).

Cyclization of epoxyolyprene 28

Using Et₂AlCl as Lewis acid

Following the general procedure, reaction of epoxide **28** with Et₂AlCl for 50 min provided after flash column chromatography (H:MTBE, 95:5) aldehyde **31** (5%), compound **29** (6%), compound **30** (5%), compound **32** (24%) and compounds **33** (12%) and **34** (9%).

(R,8E,12E,16E)-4,8,13,17,21-pentamethyl-5-(propan-2-ylidene)docosa-8,12,16,20-tetraenal (31).

Colourless oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 9.73 (t, *J* = 1.8 Hz, 1H), 5.27 – 5.08 (m, 4H), 2.74 (tq, *J* = 7.4, 6.9 Hz, 1H), 2.34 (td, *J* = 7.4, 1.9 Hz, 2H), 2.12 – 1.95 (m, 16H), 1.70 (s, 6H), 1.67 (q, *J* = 7.4 Hz, 2H), 1.66 (s, 6H), 1.63 (s, 3H), 1.62 (s, 6H), 1.02 (d, *J* = 6.9 Hz, 3H). ¹³C {¹H} NMR (126 MHz, CDCl₃) δ 202.9 (CH), 135.8, 135.2, 134.9, 134.5, 131.3, 126.6 (C), 124.4, 124.3, 124.3, 124.0 (CH), 42.5, 40.4, 39.8, 39.8 (CH₂), 35.3 (CH), 28.3, 28.3, 27.8, 26.9, 26.8, 26.7 (CH₂), 25.7, 21.0, 20.1, 19.6, 17.7, 16.1, 16.1, 16.0 (CH₃). HRMS (ESI-QTOF) *m/z*: [M + H]⁺ Calcd for C₃₀H₅₀O 427,3862, Found 427.3930.

(1R,2S,4S)-1,3,3-trimethyl-2-((3E,7E,11E)-3,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-yl)-7-oxabicyclo[2.2.1]heptane (29). Colourless oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 5.19 – 5.10 (m,

4H), 3.74 (d, $J = 5.4$ Hz, 1H), 2.14 – 1.88 (m, 16H), 1.70 (s, 3H), 1.62 (s, 12H), 1.51 – 1.39 (m, 4H),
1.35 (s, 3H), 1.20 (dd, $J = 8.6, 5.7$ Hz, 1H), 1.07 (s, 3H), 1.04 (s, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz,
CDCl₃) δ 135.39, 135.21, 134.94, 131.27 (C), 124.5, 124.4, 124.3, 124.3 (CH), 86.7 (C), 86.1 (CH),
55.2 (CH), 45.3 (C), 39.8, 39.8, 39.8, 39.0, 28.3, 28.2, 26.8, 26.7, 26.2 (CH₂), 26.1 (CH₃), 25.8 (CH₂),
25.7, 23.4, 18.9, 17.7, 16.1, 16.0, 16.0 (CH₃).

(2*R*,3*S*,4*R*)-2,3,4-trimethyl-3-((3*E*,7*E*,11*E*)-3,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-
yl)cyclohexan-1-one (**30**). Colourless oil. ^1H NMR (500 MHz, Chloroform-*d*) δ 5.22 – 5.09 (m, 4H),
2.51 (q, $J = 6.7$ Hz, 1H), 2.40 – 2.34 (m, 2H), 2.13 – 1.98 (m, 15H), 1.92 – 1.81 (m, 2H), 1.70 (s, 3H),
1.65 (s, 3H), 1.63 (s, 9H), 1.47 – 1.36 (m, 2H), 0.96 (d, $J = 6.7$ Hz, 3H), 0.92 (d, $J = 6.8$ Hz, 3H), 0.60
(s, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl₃) δ 214.0, 135.3, 135.2, 135.0, 131.3 (C), 124.4, 124.4, 124.3,
124.2, 50.5 (CH), 43.5(C), 41.6, 39.8, 39.8, 36.2 (CH), 36.0, 32.6, 31.0, 28.3, 28.2, 26.8, 26.7 (CH₂),
25.7, 17.7, 16.2, 16.1, 16.0, 15.4, 15.1, 7.6 (CH₃).

(2*S*,4*aS*,5*R*,6*R*)-1,1,5,6-tetramethyl-5-((3*E*,7*E*)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)-
1,2,3,4,4*a*,5,6,7-octahydronaphthalen-2-ol (**32**). Colourless oil. A fraction enriched in **32** was subjected
to HPLC (normal phase, H:MTBE 95:5, $R_t = 26.8$ min) to give pure **32**. ^1H NMR (500 MHz, DMSO-*d*₆)
 δ 5.30 (dt, $J = 3.9, 2.0$ Hz, 1H), 5.14 – 5.08 (m, 3H), 3.34 (q, $J = 3.5$ Hz, 1H), 2.12 – 1.81 (m, 14H),
1.66 (s, 3H), 1.65 – 1.60 (m, 2H), 1.58 (s, 9H), 1.54 – 1.44 (m, 2H), 1.37 – 1.27 (m, 1H), 1.25 – 1.16
(m, 1H), 1.04 (s, 3H), 1.02 (s, 3H), 0.84 (s, 3H), 0.79 (d, $J = 6.6$ Hz, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz,
DMSO) δ 143.7, 134.8, 134.0, 130.9 (C), 125.9, 124.7, 124.5, 117.0, 75.46 (CH), 41.6 (C), 39.7 (CH),
39.6 (CH₂), 36.3 (C), 35.0 (CH₂), 33.0 (CH), 31.3, 30.0, 30.0 (CH₂), 27.4 (CH₃), 26.8, 26.5(CH₂), 25.7,
25.3 (CH₃), 22.2, 22.2 (CH₂), 22.1, 17.9, 16.3, 16.1, 14.9 (CH₃).

Thalianol (**33**). A fraction enriched in **33** was subjected to HPLC (normal phase, H:MTBE 95:5, $R_t =$
45.3 min) to give pure **33**. Colourless oil. ^1H NMR (500 MHz, Chloroform-*d*) δ 5.12 (bt, $J = 6.9$ Hz,
1H), 5.10 (bt, $J = 6.9$ Hz, 1H), 3.26 (dd, $J = 11.6, 4.4$ Hz, 1H), 2.21 – 1.82 (m, 9H), 1.78 – 1.70 (m, 5H),
1.69 (bs, 3H), 1.66 – 1.62 (m, 2H), 1.61 (bs, 6H), 1.57 – 1.42 (m, 3H), 1.35 (ddd, $J = 9.9, 6.6, 2.8$ Hz,

1H), 1.31 – 1.21 (m, 2H), 1.09 – 1.04 (m, 1H), 1.02 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H), 0.82 (s, 3H), 0.71 (d, $J = 6.6$ Hz, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, cdcl_3) δ 143.2, 138.2, 134.7, 131.3 (C), 125.0, 124.4, 79.2 (CH), 52.6 (C), 51.5 (CH), 39.7 (CH₂), 38.7 (C), 38.4 (CH), 35.7 (C), 35.6, 31.7, 30.8 (CH₂), 28.2 (CH₃), 27.9, 27.8, 26.8, 26.6 (CH₂), 25.7 (CH₃), 25.2 (CH₂), 23.4 (CH₃), 19.4 (CH₂), 19.0, 17.7, 16.0, 15.5, 14.7 (CH₃).

14-Epi-thalianol (34). A fraction enriched in **34** was subjected to HPLC (normal phase, H:MTBE 95:5, $R_t = 38.3$ min) to give pure **34**. Colourless oil. ^1H NMR (500 MHz, Chloroform-*d*) δ 5.11 (bt, $J = 6.9$ Hz, 1H), 5.10 (bt, $J = 6.9$ Hz, 1H), 3.28 (dd, $J = 11.6, 4.4$ Hz, 1H), 2.22 – 1.83 (m, 10H), 1.79 – 1.71 (m, 5H), 1.71 (bs, 3H), 1.69 – 1.64 (m, 3H), 1.62 (d, $J = 6.1, 1.4$ Hz, 6H), 1.47 (ddd, $J = 12.1, 6.4, 1.8$ Hz, 1H), 1.35 – 1.26 (m, 3H), 1.09 (dd, $J = 12.3, 1.5$ Hz, 1H), 1.04 (s, 3H), 0.96 (d, $J = 6.7$ Hz, 6H), 0.86 (d, $J = 6.8$ Hz, 3H), 0.84 (s, 3H). ^{13}C $\{^1\text{H}\}$ NMR (126 MHz, CDCl_3) δ 143.4, 138.0, 134.9, 131.3 (C), 125.0, 124.4, 79.3 (CH), 52.8 (C), 51.6 (CH), 39.8 (CH₂), 38.8 (C), 38.2 (CH), 35.8, 35.6 (C), 32.2, 30.8 (CH₂), 28.2 (CH₃), 27.9, 27.6, 26.8, 26.5 (CH₂), 25.7, 25.2 (CH₃), 23.4 (CH₂), 19.5 (CH₃), 19.0 (CH₂), 17.7, 16.0, 15.5, 14.3 (CH₃).

Using GaCl₃ as Lewis acid

To a solution of starting material **28** (1 mmol) in dry DCM (30 mL) was added gallium trichloride (0.01 mmol) at room temperature. The reaction mixture was further stirred until disappearance of the starting material. Then, solvent was removed under reduced pressure and the crude reaction mixture passed through a short plug of silica gel which was washed with TBME. Finally the crude resultant was concentrated under reduced pressure and then purified by flash chromatography in silica column (H:MTBE, 95:5) to obtain compound **29** (10%), compound **30** (9%), compound **32** (25%) and compounds **33** (18%) and **34** (6%).

ASSOCIATED CONTENT

Supporting Information.

This material is available free of charge via on the ACS Publications website at DOI:

Copies of ^1H and ^{13}C NMR spectra, and computational data (PDF).

AUTHOR INFORMATION**Corresponding Author**

* Email: jfquilez@ugr.es

* Email: afbarre@ugr.es

* Email: lopez@usal.es

ORCID

José F. Quílez del Moral: 0000-0003-4806-6693

Alejandro. F. Barrero: 0000-0002-3058-8760

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support for this work was provided by the Junta de Andalucía (P08-FQM-3596) and Ministerio de Economía y Competitividad (CTQ-2015-64049-C3-3-R).

REFERENCES

(1) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. Cascade Reactions in Total Synthesis. *Angew. Chem. Int. Ed.* **2006**, *45*, 7134–7186

1 (2) Nicolaou, K. C.; Li, J. “Biomimetic” Cascade Reactions in Organic Synthesis: Construction of 4-
2 Oxatricyclo[4.3.1.0]decan-2-one Systems and Total Synthesis of 1-O-Methylforbesione via Tandem
3 Claisen Rearrangement/Diels–Alder Reactions. *Angew. Chem. Int. Ed.* **2001**, *40*, 4264–4268.
4
5

6
7
8 (3) (a) Yoder, R. A.; Johnston, J. N. A Case Study in Biomimetic Total Synthesis: Polyolefin
9 Carbocyclizations to Terpenes and Steroids. *Chem. Rev.* **2005**, *105*, 4730–4756. (b) Zogafros A. L.
10 From Biosynthesis to Total Synthesis: Strategies and Tactics for Natural Products. 1st ed., Wiley, **2016**.
11
12 (c) Barrett, A. G. M.; Ma, T.; Mies, T. Recent Developments in Polyene Cyclizations and Their
13 Applications in Natural Product Synthesis. *Synthesis* **2019**, *51*, 67–82. (d) Tian, Y.; Xu, X.; Zhang, L.;
14 Qu, J. Tetraphenylphosphonium Tetrafluoroborate / 1, 1, 1, 3, 3,3 Hexafluoroisopropanol (Ph₄PBF₄ /
15 HFIP) Effecting Epoxide-Initiated Cation–Olefin Polycyclizations. *Org. Lett.* **2016**, *18*, 268–271. (e)
16 Zhang, F. –Z.; Tian, Y.; Li, G. –X.; Qu, J. Intramolecular Etherification and Polyene Cyclization of π -
17 Activated Alcohols Promoted by Hot Water. *J. Org. Chem.* **2015**, *80*, 1107–1115.
18
19
20
21
22
23
24
25
26
27
28

29 (4) De la Torre, M. C.; Sierra, M. A. Comments on Recent Achievements in Biomimetic Organic
30 Synthesis. *Angew. Chem. Int. Ed.* **2004**, *43*, 160–181.
31
32
33

34 (5) Wendt, K. U.; Schulz, G. E.; Corey, E. J.; Liu, D. R. Enzyme Mechanisms for Polycyclic
35 Triterpene Formation. *Angew. Chem. Int. Ed.* **2000**, *39*, 2812–2833.
36
37
38
39

40 (6) Van Tamelen, E. E.; Nadeau R. G. Laboratory Cyclization of Geranylgeranyl Acetate Terminal
41 Epoxide. *J. Am. Chem. Soc.* **1967**, *89*, 176–177.
42
43
44

45 (7) Fish, P. V.; Sudhakar, A. R.; Johnson, W. S. Epoxide-initiated Cationic Polyene Cyclisations.
46 *Tetrahedron Lett.* **1993**, *34*, 7849–7852.
47
48
49

50 (8) Corey, E. J.; Lin, S. A. A Short Enantioselective Total Synthesis of Dammarenediol II. *J. Am.*
51 *Chem. Soc.* **1996**, *118*, 8765–8766.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (9) Surendra, K.; Corey, E. J. Rapid and Enantioselective Synthetic Approaches to Germanicol and Other Pentacyclic Triterpenes. *J. Am. Chem. Soc.* **2008**, *130*, 8865–8869.
- (10) Surendra, K.; Corey, E. J. A Short Enantioselective Total Synthesis of the Fundamental Pentacyclic Triterpene Lupeol. *J. Am. Chem. Soc.* **2009**, *131*, 13928–13929.
- (11) Zhao, Y.-J., Serena Tan, L.-J., Li, B., Li, S.-M. Loh, T.-P. Bio-inspired Polyene Cyclization: Aziridinyl Polyene Cyclization Catalyzed by InBr₃. *Chem. Commun.* **2009**, 3738–3740.
- (12) Snyder, S. A.; Treitler, D. S.; Brucks, A. P. Simple Reagents for Direct Halonium-Induced Polyene Cyclizations. *J. Am. Chem. Soc.* **2010**, *132*, 14303–14314.
- (13) Shenvi, R. A.; Corey, E. J. Synthetic Access to Bent Polycycles by Cation- π Cyclization. *Org. Lett.* **2010**, *12*, 3548–3551.
- (14) Pronin, S. V.; Shenvi, R. A. Synthesis of Highly Strained Terpenes by Non-stop Tail-to-head Polycyclization. *Nature Chem.* **2012**, *4*, 915–920.
- (15) Rajendar, G.; Corey, E. J. A Systematic Study of Functionalized Oxiranes as Initiating Groups for Cationic Polycyclization Reactions. *J. Am. Chem. Soc.* **2015**, *137*, 5837–5844.
- (16) Alonso, P.; Pardo, P.; Galván, A.; Fañanas, F. J.; Rodríguez, F. Synthesis of Cyclic Alkenyl Triflates by a Cationic Cyclization Reaction and its Application in Biomimetic Polycyclizations and Synthesis of Terpenes. *Angew. Chem. Int. Ed.* **2015**, *54*, 15506–15510.
- (17) Nakano C.; Hoshino, T. Characterization of the Rv3377c Gene Product, a Type-B Diterpene Cyclase, from the Mycobacterium tuberculosis H37 Genome. *ChemBioChem* **2009**, *10*, 2060–2071.
- (18) Gao, Y.; Honzatko, R. B.; Peters, R. B. Terpenoid Synthase Structures: a So Far Incomplete View of Complex Catalysis. *Nat. Prod. Rep.* **2012**, *29*, 1153–1175.

1 (19) Potter, K. C.; Jia, M.; Hong, Y. J.; Tantillo, D.; Peters, R. J. Product Rearrangement from
2 Altering a Single Residue in the Rice syn-Copalyl Diphosphate Synthase. *Org. Lett.* **2016**, *18*, 1060-
3 1063.
4
5

6
7
8 (20) Schulte, S.; Potter, K. C.; Lemke, C.; Peters, R. J. Catalytic Bases and Stereocontrol in
9 Lamiaceae Class II Diterpene Cyclases. *Biochemistry* **2018**, *57*, 3473–3479.
10
11

12
13 (21) Heinemann, C.; Demuth, M. Short Biomimetic Synthesis of a Steroid by Photoinduced Electron
14 Transfer and Remote Asymmetric Induction. *J. Am. Chem. Soc.* **1999**, *121*, 4894–4895.
15
16

17
18 (22) Justicia, J.; Álvarez de Cienfuegos, L.; Campaña, A. G.; Miguel, D.; Jakoby, Z.; Gansäuer A.;
19 Cuerva, J. M. Bioinspired Terpene Synthesis: a Radical Approach. *Chem. Soc. Rev.* **2011**, *40*, 3525–
20 3537.
21
22
23

24
25 (23) Barrero, A. F.; Cuerva, J. M.; Herrador, M. M.; Valdivia, M. V. A New Strategy for the Synthesis
26 of Cyclic Terpenoids Based on the Radical Opening of Acyclic Epoxypolyenes. *J. Org. Chem.* **2001**, *66*,
27 4074–4078.
28
29
30

31
32 (24) Ishihara, K.; Nakamura, S.; Yamamoto, H. The First Enantioselective Biomimetic Cyclization of
33 Polyprenoids. *J. Am. Chem. Soc.* **1999**, *121*, 4906–4907.
34
35
36

37
38 (25) Nakamura, S.; Ishihara K.; Yamamoto, H. Enantioselective Biomimetic Cyclization of
39 Isoprenoids Using Lewis Acid-Assisted Chiral Brønsted Acids: Abnormal Claisen Rearrangements and
40 Successive Cyclizations. *J. Am. Chem. Soc.* **2000**, *122*, 8131–8140.
41
42
43
44

45
46 (26) Ishihara, K.; Ishibashi, H.; Yamamoto, H. Enantio- and Diastereoselective Stepwise Cyclization
47 of Polyprenoids Induced by Chiral and Achiral LBAs. A New Entry to (–)-Ambrox, (+)-Podocarpa-
48 8,11,13-triene Diterpenoids, and (–)-Tetracyclic Polyprenoid of Sedimentary Origin. *J. Am. Chem. Soc.*
49 **2002**, *124*, 3647–3655.
50
51
52
53
54
55
56
57
58
59
60

1 (27) Zhao, Y.-J.; Li, B.; Serena Tan, L.-J.; Shen, Z.-L.; Loh, T.-P. Enantioselective Cationic Polyene
2 Cyclization vs Enantioselective Intramolecular Carbonyl–Ene Reaction. *J. Am. Chem. Soc.* **2010**, *132*,
3 10242–10244.
4

5
6
7 (28) Surendra, K.; Qiu, W.; Corey, E. J. A Powerful New Construction of Complex Chiral Polycycles
8 by an Indium(III)-Catalyzed Cationic Cascade. *J. Am. Chem. Soc.* **2011**, *133*, 9724–9726.
9

10
11
12 (29) Zhou, S.; Chen, H.; Luo, Y.; Zhang, W., Li, A. Asymmetric Total Synthesis of Mycoleptodiscin
13 A. *Angew. Chem. Int. Ed.* **2015**, *54*, 6878–6882.
14
15

16
17
18 (30) Abe, I. Enzymatic synthesis of cyclic triterpenes. *Nat. Prod. Rep.* **2007**, *24*, 1311–1331.
19

20
21
22 (31) Van Tamelen, E. E.; Sharpless, K. B. Terpene Terminal Epoxides. Skeletal Rearrangement
23 Accompanying Bicyclization of Squalene 2,3-Oxide. *J. Am. Chem. Soc.* **1969**, *91*, 1848–1849.
24
25

26
27 (31) Van Tamelen, E. E.; Willet, J.; Schwartz, M.; Nadeau, R. Nonenzymic Laboratory Cyclization of
28 Squalene 2,3-Oxide. *J. Am. Chem. Soc.* **1966**, *88*, 5937–5938.
29
30

31
32
33 (32) Corey, E. J.; Virgil, S. C. Enantioselective Total Synthesis of a Protosterol, 3 β ,20-
34 Dihydroxyprotost-24-ene. *J. Am. Chem. Soc.* **1990**, *112*, 6429–6431.
35
36

37
38 (33) Corey, E. J.; Roberts, B. E. The Application of a Shapiro Reaction - Suzuki Coupling Sequence
39 to the Stereoselective Synthesis of *E*-Trisubstituted Olefins. *Tetrahedron Lett.* **1997**, *38*, 8921–8924.
40
41

42
43 (34) Marcos I. S.; Sexmero, M. J.; Hernández, F. A.; Corrales, M., Pilar Basabe; P., Díez D.; Urones,
44 J. G. Synthetic Studies Towards the ent-Labdane Diterpenoids: Rearrangement of ent-Halimanes.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Molecules **2006**, *11*, 792–807.

(35) George, J. H.; McArdle, M.; Baldwin, J. E.; Adlington, R. M. Biomimetic Rearrangements of
Simplified Labdane Diterpenoids. *Tetrahedron* **2010**, *66*, 6321–6330.

(36) Zhou, M.; Geng, H.-C.; Zhang, H.-B.; Dong, K.; Wang, W.-G.; Du, X.; Li, X.-N.; He, F.; Qin, H.-B.; Li, Y.; Pu, J.-X.; Sun, H.-D. N. Scopariusins, A New Class of ent-Halimane Diterpenoids Isolated from *Isodon scoparius*, and Biomimetic Synthesis of Scopariusin A and Isoscoparin N. *Org. Lett.* **2013**, *15*, 314–317.

(37) Rosales, A.; Muñoz-Bascón, J.; Roldan-Molina, E.; Rivas-Bascón, N.; Padial, N. M.; Rodríguez-Maecker, R.; Rodríguez-García, I.; Oltra, J. E. Synthesis of (±)-Aureol by Bioinspired Rearrangements. *J. Org. Chem.* **2015**, *80*, 1866–1870.

(38) Abe, I.; Rohmer, M.; Prestwich, G. D. Enzymatic Cyclization of Squalene and Oxidosqualene to Sterols and Triterpenes. *Chem. Rev.* **1993**, *93*, 2189–2206.

(39) Roncero, A. M.; Tobal, I. E.; Moro, R. F.; Díez, D.; Marcos, I. S. Halimane diterpenoids: sources, structures, nomenclature and biological activities. *Nat. Prod. Rep.* **2018**, *35*, 955–991.

(40) (a) Kunesch, N.; Cavé, A.; Leboeuf, M.; Hocquemiller, R.; Dubois, G. L'isopolyalthenol et le Neopolyalthenol, Nouveaux Indolosesquiterpenes Isoles de *Polyalthia suaveolens*, Annonacees. *Tetrahedron Lett.* **1985**, *26*, 4937–4940. (b) Nakamura, H.; Wu, H.; Ohizumi, Y.; Hirata, Y. Agelasine-A, -B, -C and -D, Novel Bicyclic Diterpenoids with a 9-Methyladeninium Unit Possessing Inhibitory Effects on Na,K-ATPase from the Okinawan Sea Sponge *Agelas* sp. *Tetrahedron Lett.* **1984**, *25*, 2989–2992.

(41) Zhou, M.; Geng, H.-C.; Zhang, H.-B.; Dong, K.; Wang, W.-G.; Du, X.; Li, X.-N.; He, F.; Qin, H.-B.; Li, Y.; Pu, J.-X.; Sun, H.-D. Scopariusins, A New Class of ent-Halimane Diterpenoids Isolated from *Isodon scoparius*, and Biomimetic Synthesis of Scopariusin A and Isoscoparin N. *Org. Lett.* **2013**, *15*, 314–317.

(42) Mann, F. M.; Peters, R. J. Isotuberculosinol: the Unusual Case of an Immunomodulatory Diterpenoid from *Mycobacterium tuberculosis*. *Med. Chem. Commun.* **2012**, *3*, 899–904.

(43) Gunasekera, S. P.; McCarthy, P. J.; Kelly-Borges, M. Dysidiolide: A Novel Protein Phosphatase Inhibitor from the Caribbean Sponge *Dysidea etheria* de Laubenfels. *J. Am. Chem. Soc.* **1996**, *118*, 8759–8760.

(44) Layre, E.; Lee, H. J.; Young, D. C.; Martinot, A. J.; Buter, J.; Minnaard, A. J.; Annand, J. W.; Fortune, S. M.; Snider, B. B.; Matsunaga, I.; Rubin, E. J.; Alber, T.; Moody, D. B. Molecular Profiling of *Mycobacterium tuberculosis* Identifies Tuberculosinyl Nucleoside Products of the Virulence-associated Enzyme Rv3378c. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 2978–2983.

(45) Peters, R. J. Two Rings in Them All: The Labdane-related Diterpenoids. *Nat. Prod. Rep.* **2010**, *27*, 1521–1530.

(46) Global Tuberculosis Report. World Health Organization. http://www.who.int/tb/publications/global_report/en/ **2015**.

(47) Mangel, N.; Mann, F. M.; Hillwig, M. L.; Peters, R. J.; Snider, B. B. Synthesis of (±)-Nosyberkol (Isotuberculosinol, Revised Structure of Edaxadiene) and (±)-Tuberculosinol. *Org. Lett.*, **2010**, *12*, 2626–2629.

(48) Spangler, J. E.; Carson, C. A.; Sorensen, E. J. Synthesis enables a structural revision of the *Mycobacterium tuberculosis*-produced diterpene, edaxadiene. *Chem. Sci.* **2010**, *1*, 202–205.

(49) Van Tamelen, E. E.; Marson S. A. Total Biogenetic-type Synthesis of (±)-Isopimaradienols and (±)-Araucarol. *J. Am. Chem. Soc.* **1975**, *97*, 5614–5616.

(50) Corey, E. J.; Sodeoka, M. An Effective System for Epoxide-Initiated Cation-Olefin Cyclization. *Tetrahedron Lett.* **1991**, *32*, 7005–7008.

(51) Smentek, L.; Hess, B. A. Jr. Compelling Computational Evidence for the Concerted Cyclization of the ABC Rings of Hopene from Protonated Squalene. *J. Am. Chem. Soc.* **2010**, *132*, 17111–17117.

- (52) Hess, B. A. Jr. Computational Studies on the Cyclization of Squalene to the Steroids and Hopenes. *Org. Biomol. Chem.* **2017**, *15*, 2133–2145.
- (53) Rajamani, R.; Gao, J. Balancing Kinetic and Thermodynamic Control: the Mechanism of Carbocation Cyclization by Squalene Cyclase. *J. Am. Chem. Soc.* **2003**, *125*, 12768–12781.
- (54) Domingo, V.; Arteaga, J. F.; Quílez del Moral, J. F.; Barrero A. F. Unusually Cyclized Triterpenes: Occurrence, Biosynthesis and Chemical Synthesis. *Nat. Prod. Rep.*, **2009**, *26*, 115-134.
- (55) Potter, K. C.; Zi, J.; Hong, Y. J.; Schulte, S.; Malchow, B.; Tantillo, D. J.; Peters, R. J. Blocking Deprotonation with Retention of Aromaticity in a Plant *ent*-Copalyl Diphosphate Synthase Leads to Product Rearrangement. *Angew. Chem., Int. Ed.* **2016**, *55*, 634–638.
- (56) Vidari, G., Beszant, S.; El Merabet, J.; Bovolenta, M.; Zanoni, G. FeCl₃ and ZrCl₄ Regiochemically Controlled Biomimetic-like Cyclizations of Simple Isoprenoid Epoxyolefins. *Tetrahedron Lett.* **2002**, *43*, 2687–2690.
- (57) Domingo, V.; Arteaga, J. F.; López-Pérez, J. L.; Peláez, R.; Quílez del Moral, J. F.; Barrero A. F. Total Synthesis of (+)-*seco*-C-Oleanane via Stepwise Controlled Radical Cascade Cyclization. *J. Org. Chem.* **2012**, *77*, 341–350.
- (58) Coates, R. M.; Ley, D. A.; Cavender, P. L. Synthesis and Carbon-13 Nuclear Magnetic Resonance Spectra of *all-trans*-Geranylgeraniol and its Nor Analogs. *J. Org. Chem.* **1978**, *43*, 4915–4922.
- (59) Wang, W.-Q.; Yin, Y.-P.; Jun, L.; Xuan, L. J. Halimane-type Diterpenoids from *Vitex rotundifolia* and their Anti-hyperlipidemia Activities. *Phytochemistry* **2018**, *146*, 56–62.
- (60) Jia, M.; Potter, K. C.; Peters, R. J. Extreme Promiscuity of a Bacterial and a Plant Diterpene Synthase. *Metab. Eng.* **2016**, 24–34.

1 (61) Justicia, J.; Oller-López J. L.; Campaña, A. G.; Oltra, J. E.; Cuerva, J. M.; Buñuel, E.; Cárdenas,
2 D. J. 7-endo Radical Cyclizations Catalyzed by Titanocene (III). Straightforward Synthesis of
3 Terpenoids with Seven-Membered Carbocycles. *J. Am. Chem. Soc.* **2005**, *127*, 14911–14921.
4

5
6
7
8 (62) Fukuda, Y.; Watanabe, T.; Hoshino, T. Mutated variants of squalene-hopene cyclase: enzymatic
9 syntheses of triterpenes bearing oxygen-bridged monocycles and a new 6,6,6,6,6-fused pentacyclic
10 scaffold, named neogammacerane, from 2,3-oxidosqualene. *Org. Biomol. Chem.* **2018**, *16*, 8365–8378.
11
12
13

14
15 (63) Abe, I.; Rohmer M. Enzymic cyclization of 2,3-dihydrosqualene and squalene 2,3-epoxide by
16 squalene cyclases: from pentacyclic to tetracyclic triterpenes. *J. Chem. Soc., Perkin Trans.*, **1994**, *1*,
17 783–791.
18
19
20
21

22
23 (64) Kolesnikova M. D.; Obermeyer A. C.; Wilson W. K.; Lynch D. A.; Quanbo Xiong Q.; Matsuda
24 S. P. Stereochemistry of water addition in triterpene synthesis: the structure of arabidiol. *Org. Lett.*
25 **2007**, *9*, 2183–2186.
26
27
28
29

30
31 (65) Tsangarakis, C.; Raptis, C.; Arkoudis, E.; Stratakis, M. Zeolite NaY-Promoted Monocyclization
32 of Epoxy Polyene Terpenes: A Unique Route for the Direct Synthesis of Incompletely Cyclized
33 Naturally Occurring Terpenols. *Adv. Synth. Catal.* **2008**, *350*, 1587–1600.
34
35
36
37

38 (66) Li, H-J.; Regis Guillot, R.; Gandon, V.; A Gallium-Catalyzed Cycloisomerization /Friedel-Crafts
39 Tandem. *J. Org. Chem.* **2010**, *75*, 8435–8449.
40
41
42
43

44 (67) Jakupovic, J.; Banerjee, S.; Bohlmann, F.; Kinga, R. M.; Robinson, H. New diterpenes from
45 *Chiliotrichium rosmarinifolium* and *Nardophyllum lanatum*. *Tetrahedron* **1986**, *42*, 1305–1313.
46
47
48

49 (68) Facio, G. C.; Xu, R.; Matsuda, S. P. T. Genome Mining To Identify New Plant Triterpenoids. *J.*
50 *Am. Chem Soc.* **2004**, *126*, 5678–5679.
51
52
53
54
55
56
57
58
59
60